

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110418 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number:
PCT/US2004/018502

(22) International Filing Date: 10 June 2004 (10.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/477,721 10 June 2003 (10.06.2003) US

(71) Applicant (for all designated States except US): **KALYPSYS, INC.** [US/US]; 11099 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WASH, Paul, L.** [US/US]; 3620 Park Blvd., Apt. 11, San Diego, CA 92103 (US). **WILEY, Brandon, M.** [US/US]; 241 La Veta Avenue, Encinitas, CA 92024 (US). **HASSIG, Christian** [US/US]; 8818 Capceno Road, San Diego, CA 92126 (US). **MALECHA, James, W.** [US/US]; 4482 Philbrook Square, San Diego, CA 92130 (US). **NOBLE, Stewart, A.** [GB/US]; 5632 Shannon Ridge Lane, San Diego, CA 92130 (US).

(74) Agent: **BLAYLOCK, Richard, L.**; Pillsbury Winthrop, LLP, 11682 El Camino Real, Suite 200, San Diego, CA 92130-1593 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:




— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE



(57) Abstract: Disclosed herein are carbonyl compounds of Formula (I), (II) or (III), and others as described herein. Also disclosed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, autoimmune diseases and cardiovascular conditions, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE

CROSS REFERENCE TO RELATED APPLICATION

This Application claims priority of U.S. provisional application Serial No. 60/477,721, filed June 10, 2003.

FIELD OF THE INVENTION


[0001] The present invention is directed to carbonyl compounds as inhibitors of histone deacetylase (HDAC). These compounds are useful in treatments of disease states, including, but not limited to, certain cancers (such as colon cancer, breast cancer, ovarian cancer, lung cancer, prostate cancer, cancers of the pancreas, cervix, uteri, kidney, brain and central nervous system, non-Hodgkin's lymphoma, multiple myeloma and hematopoietic malignancies including leukemias (Chronic Lymphocytic Leukemia) and lymphomas), neurological disorders, including polyglutamine-repeat disorders (such as Huntington's disease, Spinocerebellar ataxia 1 (SCA 1), Machado-Joseph disease (MJD)/Spinocerebella ataxia 3 (SCA 3), Kennedy disease/Spinal and bulbar muscular atrophy (SBMA) and Dentatorubral pallidolusyan atrophy (DRPLA), anemias and thalassemia (such as Sickle Cell Disease (SCD), inflammatory conditions (such as Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), ulcerative colitis and psoriasis) autoimmune diseases (such as Systemic Lupus Erythromatosus (SLE) and Multiple Sclerosis (MS)) and cardiac hypertrophy and heart failure.

BACKGROUND OF THE INVENTION

[0002] Histone proteins organize DNA into nucleosomes, which are regular repeating structures of chromatin. The acetylation status of histones alters chromatin structure, which, in turn, is involved in gene expression. Two classes of enzymes can affect the acetylation of histones - histone acetyltransferases (HATs) and histone deacetylases (HDACs). A number of HDAC inhibitors have been characterized. However, to date no effective candidate for cancer therapy has been identified. Therefore, there is a need in the art to discover HDAC inhibitors that have effective anti-tumor activity.

SUMMARY OF THE INVENTION

[0003] Disclosed herein are carbonyl compounds of Formula I, II, or III and related Formulae IV, V, VI VII, or VIII, as described herein, including their pharmaceutically acceptable salts, esters, and prodrugs.




[0004] Also disclosed are pharmaceutical compositions comprising a compound having structural formulae I, II, III, IV, V, VI, VII or VIII which are capable of inhibiting the catalytic activity of histone deacetylase (HDAC).

[0005] Also disclosed are methods of treating diseases in mammals, including humans, such as cancer, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0006] An aspect of the present invention relates to a compound of Formula I



or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, wherein

a) R₁-R₅ is each independently selected from the group consisting of

- i) hydrogen;
- ii) lower alkyl;
- iii) lower alkylene;
- iv) halogen or perhaloalkyl;
- v) an alkoxy of formula -(X₁)_{n1}-O-X₂, where

X₁ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X₂ is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl; and

n₁ is 0, 1, 2, or 3; and

- vi) a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

- A) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where
 X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl;
 and
 $n1$ is 0, 1, 2, or 3
- C) halogen or perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where
 X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and
 $n3$ is 0 or 1;
- G) a thioether or thiol of formula $-(X_6)_{n6}-S-X_7$, where
 X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_7 is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl;
 and
 $n6$ is 0, 1, 2, or 3; and
- H) an amide of formula $-(X_7)_{n7}-NH-C(O)-X_8$ or $-(X_9)_{n9}-C(O)-NH-X_{10}$

X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, heteroalkyl, aryl, and heteroaryl;

n_7 and n_9 are each independently is 0 or 1;

vii) an acyl of formula $-(X_1)_{n1}-C(O)-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, heteroaryl, hydroxy, alkoxy, amino, and $-NH-X_3$,

where X_3 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, amino, and amide; and

n_1 is 0, 1, 2, or 3; and

viii) cyano;

ix) nitro;

x) an amino of formula $-(X_{15})_{n15}-NX_{16}X_{17}$, where

X_{15} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_{16} and X_{17} , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_{15} is 0 or 1;


xi) thioether or thiol of formula $-(X_{22})_{n22}-S-X_{23}$, where

X_{22} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{23} is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl; and

n_{22} is 0, 1, 2, or 3;

xii) an N-sulfonamido of structure



wherein

R_{18} is a lower alkyl, lower heteroalkyl, or is a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

A) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;

B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, perhaloalkyl, aryl, and heteroaryl; and

n_1 is 0, 1, 2, or 3;

C) halogen or perhaloalkyl;

D) cyano;

E) nitro;

F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the

nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0, or 1;

G) a thioether or thiol of formula $-(X_6)_{n_6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, aryl, heteroaryl, and perfluoroalkyl; and

n_6 is 0, 1, 2, or 3; and

H) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or

$-(X_9)_{n_9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, heteroaryl, heteroalkyl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, and heteroaryl, and heteroalkyl;


n_7 and n_9 are each independently is 0 or 1;

R_{20} is H, lower alkyl, lower aralkyl, or R_{20} taken together with R_{18} forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, as shown below:



and wherein i is 0, 1, 2, 3, 4;

xiii) an S-sulfonamido of formula



wherein R_{18} is lower alkyl, lower heteroalkyl, or a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

A) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;

B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, perhaloalkyl, aryl, and heteroaryl; and

$n1$ is 0, 1, 2 or 3;

C) halogen or perhaloalkyl;

D) cyano;

E) nitro;

F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

$n3$ is 0 or 1;

G) a thioether or thiol of formula $-(X_6)_{n6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, aryl, perfluoroalkyl, and heteroaryl; and

n_6 is 0, 1, 2, or 3; and

H) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, and heteroaryl;

n_7 and n_9 are each independently is 0 or 1;


R_{19} is H, C_{1-5} alkyl, C_{1-5} aralkyl, or taken together with one of R_1 , R_2 , R_3 , R_4 , or R_5 , said R_{19} forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, as shown below:



i is 0, 1, 2, 3, 4;


or R_1 and R_2 , taken together along with the two ring carbons to which they are attached, or R_2 and R_3 , taken together along with the two ring carbons to which they are attached, or R_3 and R_4 , taken together along with the two ring carbons to which they are attached, or R_4 and R_5 , taken together along with the two ring carbons to which they are attached, form a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a six-membered aromatic or heteroaromatic, or a five- or six-membered heteroaromatic ring, each of which is optionally substituted with one or more substituents, W , each of which is independently selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) optionally substituted aryl;
- iv) optionally substituted heterocyclyl;
- v) an alkoxy of formula $-(X_{13})_{n13}-O-X_{14}$, where
 - X₁₃ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₁₄ is selected from the group consisting of hydrogen, lower alkyl, aryl, perhaloalkyl, and heteroaryl; and
 - n₁₃ is 0, 1, 2, or 3;
- vi) halogen or perhaloalkyl;
- vii) cyano;
- viii) nitro;
- ix) an amino of formula $-(X_{15})_{n15}-NX_{16}X_{17}$, where
 - X₁₅ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₁₆ and X₁₇ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X₁₆ and X₁₇, taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and
 - n₁₅ is 0 or 1; and
- x) a thioether or thiol of formula $-(X_{22})_{n22}-S-X_{23}$, where
 - X₂₂ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₂₃ is selected from the group consisting of hydrogen, lower alkyl, perfluoroalkyl, aryl, and heteroaryl; and
 - n₂₂ is 0, 1, 2, or 3;
- xxii) an S-sulfonamido of formula



wherein X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, lower heteroalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and

xxiii) an N-sulfonamido of structure




wherein X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, lower heteroalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

b) R_6 and R_7 are each independently selected from the group consisting of hydrogen and lower alkyl;

c) R_8 is selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) cyano;




wherein

X is selected from CH and nitrogen;

Y is selected from the group consisting of CH_2 , NH, oxygen and sulfur;

Z_1 and Z_2 are each independently selected from the group consisting of null, oxygen, sulfur, and $CR_{11}R_{12}$,

wherein R_{11} and R_{12} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy; and



v)

wherein R_{13} and R_{14} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy;

vi) optionally substituted acyl, $-C(O)R_E$, wherein $HOC(O)R_E$ is any pharmaceutically acceptable acid;

vii) or R_8 is equivalent to the balance of Formula I to form a disulfide dimer;

d) Q is selected from the group consisting of a bond, oxygen, sulfur, $-(CH_2)_m-$, $-(CH_2)_mNH-$, $-(CH_2)_m(CO)-$, $-(CH_2)_mNH(CO)-$, and $-(CH_2)_mC(O)NH-$, wherein m is 0-7, wherein if Q is not symmetric, Q may be attached in either direction; and

e) T is selected from the group consisting of oxygen, sulfur, and $-NR_{17}$, wherein R_{17} is selected from the group consisting of hydrogen, lower alkyl, and aryl.

[0007] The term “pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. Pharmaceutical salts can be obtained by reacting a compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.

[0008] The terms “physiologically acceptable” and “physiologically compatible” refers to excipients, products, or hydrolysis products of disclosed molecular embodiments of the invention. By way of example, protected thiol prodrug embodiments may release acids upon hydrolysis of the protected thiol. Physiologically acceptable excipients and acids are those that do not abrogate the biological activity or properties of the compound, and are nontoxic. “Physiologically acceptable” and “pharmaceutically acceptable” may be coextensive terms.


[0009] The term “ester” refers to a chemical moiety with formula $-(R)_n-COOR'$, where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1.

[0010] An “amide” is a chemical moiety with formula $-(R)_n-C(O)NHR'$ or $-(R)_n-NHC(O)R'$, where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1. An amide may be an amino acid or a peptide molecule attached to a molecule of the present invention, thereby forming a prodrug.

[0011] Any amine, hydroxy, or carboxyl side chain on the compounds of the present invention can be esterified or amidified. The procedures and specific groups to be used to achieve this end is known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, *Protective Groups in Organic Synthesis*, 3rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.

[0012] The term “lower perfluoroalkoxy” refers to a radical $-O-(CX_2)_nCX_3$ where X is any halogen, preferable F or Cl, and n is 1-5.

[0013] A “prodrug” refers to an agent that is converted into the parent drug *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility over the parent drug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the “prodrug”) to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. Yet another example of a prodrug are protected thiol compounds. Thiols bearing hydrolyzable protecting groups can unmask protected SH groups prior to or simultaneous to use.



[0014] The term thiol protecting group refers to thiols bearing hydrolyzable protecting groups that can unmask protected SH groups prior to or simultaneous to use. Preferred thiol protecting groups include but are not limited to thiol esters which release pharmaceutically acceptable acids along with an active thiol moiety. Such pharmaceutically acceptable acids are generally nontoxic and do not abrogate the biological activity of the active thiol moiety. Examples of pharmaceutically acceptable acids include, but are not limited to:

N,N-diethylglycine;

4-ethylpiperazinoacetic acid;

ethyl 2-methoxy-2-phenylacetic acid;

N,N-dimethylglycine;

(nitrophenoxysulfonyl)benzoic acid;

Acetic acid;

Maleic acid;

Fumaric acid;

Benzoic acid;

Tartronic acid;

Natural amino acids (like glutamate, aspartate, cyclic aminoacids such as proline);

D-amino acids;

Butyric acid;

Fatty acids like palmitic acid, stearic acid, oleate;

Pipecolic acid;

Phosphonic acid;

Phosphoric acid;

pivalate (trimethylacetic acid);

Succinic acid;

Cinnamic acid;

Anthranilic acid;

Salicylic acid;

Lactic acid; and

Pyruvic acids.

[0015] The term "aromatic" refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes both carbocyclic aryl (e.g., phenyl)

and heterocyclic aryl groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups. The term "carbocyclic" refers to a compound which contains one or more covalently closed ring structures, and that the atoms forming the backbone of the ring are all carbon atoms. The term thus distinguishes carbocyclic from heterocyclic rings in which the ring backbone contains at least one atom which is different from carbon. The term "heteroaromatic" or "heteroaryl" refers to an aromatic group which contains at least one heterocyclic ring.

[0016] A carbocyclic or heterocyclic ring may be aliphatic. In this case, the ring is either completely saturated, or if there is unsaturation, the conjugation of the pi-electrons in the ring do not give rise to aromaticity. The term "heterocyclyl" thus refers to a heterocyclic aliphatic or a heterocyclic aromatic (i.e., a heteroaryl) ring. Likewise, the term "carbocyclyl" refers to a carbocyclic aliphatic or a carbocyclic aromatic (i.e., an aryl) ring.

[0017] As used herein, the term "alkyl" refers to an aliphatic hydrocarbon group. The alkyl moiety may be a "saturated alkyl" group, which means that it does not contain any alkene or alkyne moieties. The alkyl moiety may also be an "unsaturated alkyl" moiety, which means that it contains at least one alkene or alkyne moiety. An "alkene" moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon double bond, and an "alkyne" moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon triple bond. The alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic.

[0018] The alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as "1 to 20" refers to each integer in the given range; e.g., "1 to 20 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, *etc.*, up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated). The alkyl group may also be a medium size alkyl having 1 to 10 carbon atoms. The alkyl group could also be a lower alkyl having 1 to 4 carbon atoms. The alkyl group of the compounds of the invention may be designated as "C₁-C₅ alkyl" or similar designations. By way of example only, "C₁-C₄ alkyl" indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.

[0019] The alkyl group may be substituted or unsubstituted. When substituted, the substituent group(s) is(are) one or more group(s) individually and independently selected from cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto,

alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Wherever a substituent is described as being "optionally substituted" that substituent may be substituted with one of the above substituents.

[0020] The substituent "R" appearing by itself and without a number designation refers to a substituent selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl (bonded through a ring carbon) and optionally substituted heteroalicyclic (bonded through a ring carbon).

[0021] An "O-carboxy" group refers to a $\text{RC}(=\text{O})\text{O}-$ group, where R is as defined herein.

[0022] A "C-carboxy" group refers to a $-\text{C}(=\text{O})\text{OR}$ groups where R is as defined herein.

[0023] An "acyl" group refers to a $-\text{C}(=\text{O})\text{R}$ group.

[0024] An "acetyl" group refers to a $-\text{C}(=\text{O})\text{CH}_3$, group.

[0025] A "trihalomethanesulfonyl" group refers to a $\text{X}_3\text{CS}(=\text{O})_2-$ group where X is a halogen.

[0026] A "cyano" group refers to a $-\text{CN}$ group.

[0027] An "isocyanato" group refers to a $-\text{NCO}$ group.

[0028] A "thiocyanato" group refers to a $-\text{CNS}$ group.

[0029] An "isothiocyanato" group refers to a $-\text{NCS}$ group.

[0030] A "sulfinyl" group refers to a $-\text{S}(=\text{O})-\text{R}$ group, with R as defined herein.

[0031] A "S-sulfonamido" group refers to a $-\text{S}(=\text{O})_2\text{NR}$, group, with R as defined herein.

[0032] A "N-sulfonamido" group refers to a $\text{RS}(=\text{O})_2\text{NH}-$ group with R as defined herein.

[0033] A "trihalomethanesulfonamido" group refers to a $\text{X}_3\text{CS}(=\text{O})_2\text{NR}-$ group with X and R as defined herein.

[0034] An "O-carbamyl" group refers to a $-\text{OC}(=\text{O})\text{-NR}_1$ group-with R as defined herein.

[0035] An "N-carbamyl" group refers to a $\text{ROC}(=\text{O})\text{NH-}$ group, with R as defined herein.

[0036] An "O-thiocarbamyl" group refers to a $-\text{OC}(=\text{S})\text{-NR}_1$ group with R as defined herein.

[0037] An "N-thiocarbamyl" group refers to an $\text{ROC}(=\text{S})\text{NH-}$ group, with R as defined herein.


[0038] A "C-amido" group refers to a $-\text{C}(=\text{O})\text{-NR}_2$ group with R as defined herein.

[0039] An "N-amido" group refers to a $\text{RC}(=\text{O})\text{NH-}$ group, with R as defined herein.


[0040] The term partially halogenated alkyl refers to an alkyl group having both hydrogen and halogen substituents.

[0041] The term "perhaloalkyl" refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.

[0042] When two substituents taken together along with the two ring carbons to which they are attached form a ring, it is meant that the following structure:



is, for example, representative of a structure such as the following:



[0043] In the above example, R_1 and R_2 , taken together along with the two ring carbons to which they are attached, form a six-membered aromatic ring.

[0044] Unless otherwise indicated, when a substituent is deemed to be "optionally substituted," it is meant that the substituent is a group that may be substituted with one or more group(s) individually and independently selected from cycloalkyl, aryl, heteroaryl,

heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. The protecting groups that may form the protective derivatives of the above substituents are known to those of skill in the art and may be found in references such as Greene and Wuts, above.



[0045] In certain embodiments, the invention relates to a compound of Formula I where R_1 - R_5 are hydrogen.

[0046] In other embodiments R_2 is an alkoxy. The alkoxy may be selected from the group consisting of methoxy, ethoxy, propoxy, n-butoxy, t-butoxy, and isobutoxy. In some embodiments, R_3 is an alkoxy.

[0047] In certain embodiments, R_3 is a halogen. "Halogen" refers to a substituent selected from the group consisting of fluorine, chlorine, bromine, and iodine. Thus, in some embodiments the halogen may be chlorine, whereas in other embodiments, the halogen may be bromine. In still other embodiments, R_3 is a perhaloalkyl. The perhaloalkyl may be selected from the group consisting of trifluoromethyl, pentafluoroethyl, and heptafluoropropyl.

[0048] In some embodiments, R_3 is a heterocyclyl. The heterocyclyl may be selected from the group consisting of furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, triazole, thiadiazole, pyran, pyridine, piperidine, morpholine,


thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine,




, and , where R is as defined herein. In some embodiments the heterocyclyl is pyrrolidine, whereas in other embodiments, the heterocyclyl is morpholine.

[0049] In certain embodiments, R_3 is $-NH(CO)R$, where R is as defined herein. In some embodiments, R is selected from hydrogen, and lower alkyl, where the alkyl may be selected from the group consisting of methyl, ethyl, propyl, n-butyl, t-butyl, and isobutyl.

[0050] In some embodiments, R_2 and R_3 , taken together along with the two ring carbons to which they are attached form a six-membered heterocyclic ring. In certain of these embodiments, the six-membered heterocyclic ring has the following structure:




Thus, in some embodiments, the compound of Formula I will have the following structure:



[0051] In some embodiments R_3 or R_4 is an optionally substituted N-sulfonamido or an optionally substituted S-sulfonamido.

[0052] In some embodiments R_3 or R_4 has the structure




wherein R_{18} is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl.

[0053] In some embodiments R_{18} is phenyl, singly or multiply substituted with C_{1-5} alkyl, C_{1-5} perhaloalkyl, C_{1-5} alkoxy, C_{1-5} perhaloalkyl alkoxy, and N-alkylamido..

[0054] In some embodiments R_6 and R_7 are hydrogen.

[0055] In certain embodiments, R_8 is cyano. In other embodiments, R_8 is




[0056] In some of these embodiments, X is nitrogen, Y is oxygen and Z_1 and Z_2 are H_2 , whereas in other embodiments, X is nitrogen, Y is NH, Z_1 is oxygen and Z_2 is H_2 . In still other embodiments, X is nitrogen, Y is NH, and Z_1 and Z_2 are oxygen, while in other embodiments, X is nitrogen, Y is sulfur, Z_1 is (H)(OH) and Z_2 is H_2 .

[0057] When Z_1 or Z_2 are H_2 , it is meant that the ring carbon to which Z_1 or Z_2 are attached forms a methylene ($-CH_2-$) group. When Z_1 or Z_2 are oxygen, it is meant that the ring carbon to which Z_1 or Z_2 are attached forms a carbonyl ($-C(O)-$) group. When Z_1 or Z_2

are (H)(OH), it is meant that the ring carbon to which Z_1 or Z_2 are attached forms a hydroxymethylene ($-\text{CH}(\text{OH})-$) group.



[0058] In certain other embodiments, R_8 is



[0059] In some of these embodiments, R_{13} and R_{14} are hydrogen, whereas in other embodiments, R_{13} is lower alkyl and R_{14} are hydrogen, where the alkyl may be selected from the group consisting of methyl, ethyl, propyl, n-butyl, t-butyl, and isobutyl.

[0060] In certain embodiments, the present invention relates to a compound of Formula I where T is sulfur. In other embodiments, T is oxygen, whereas in yet other embodiments, T is $-\text{NR}$.

[0061] In another aspect, the present invention relates to a compound of Formula II or III,



or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof,

or a pharmaceutical composition comprising such compounds,

wherein

a) T is selected from the group consisting of oxygen, sulfur, and $-\text{NR}_{17}$, wherein R_{17} is selected from the group consisting of hydrogen, lower alkyl, and aryl;

b) R_{15} and R_{16} are each independently selected from the group consisting of

i) an alkoxy of formula $-(X_1)_{n1}-\text{O}-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl; and

$n1$ is 0, 1, 2, or 3; and

ii) a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

- A) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where
 - X₁ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₂ is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl;
 - and
 - n₁ is 0, 1, 2 or 3
- C) halogen or perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where
 - X₃ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₄ and X₅ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X₄ and X₅, taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and
 - n₃ is 0 or 1;
- G) a thioether or thiol of formula $-(X_6)_{n6}-S-X_7$, where
 - X₆ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₇ is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl;
 - and
 - n₆ is 0, 1, 2, or 3; and
- H) an amide of formula $-(X_7)_{n7}-NH-C(O)-X_8$ or $-(X_9)_{n9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, and heteroaryl;

n_7 and n_9 are each independently is 0 or 1;

I) an N-sulfonamido of structure



wherein

R_{18} is a lower alkyl, lower heteroalkyl, or five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

(1) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;

(2) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl; and

n_1 is 0, 1, 2 or 3;

(3) halogen or perhaloalkyl;

(4) cyano;

(5) nitro;

(6) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0 or 1;

- (7) a thioether or thiol of formula $-(X_6)_{n_6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, perfluoroalkyl, aryl, and heteroaryl; and

n_6 is 0, 1, 2, or 3; and

- (8) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, lower heteroalkyl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, lower heteroalkyl, and heteroaryl;


n_7 and n_9 are each independently is 0 or 1;

R_{20} is H, C_{1-5} alkyl, C_{1-5} aralkyl, or taken together with R_{18} forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, having the following structure:



i is 0, 1, 2, 3, 4;

J) an S-sulfonamido of formula



wherein R_{18} is a lower alkyl, lower heteroalkyl, or five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

- (1) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- (2) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, perhaloalkyl, aryl, and heteroaryl; and

$n1$ is 0, 1, 2, or 3

- (3) halogen or perhaloalkyl;
- (4) cyano;
- (5) nitro;
- (6) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and

heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0 or 1;

- (7) a thioether or thiol of formula $-(X_6)_{n_6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl; and

n_6 is 0, 1, 2, or 3; and

- (8) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, and heteroaryl;

n_7 and n_9 are each independently 0 or 1;

wherein R_{19} is H, C_{1-5} alkyl, C_{1-5} aralkyl, or R_{19} taken together with a portion of the ring to which the S of the S-sulfonamido attaches forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, as shown below:



wherein W is independently selected from the group consisting of

- (1) hydrogen;
- (2) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- (3) optionally substituted aryl;
- (4) optionally substituted heterocyclyl;
- (5) an alkoxy of formula $-(X_{13})_{n_{13}}-O-X_{14}$, where
 X_{13} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_{14} is selected from the group consisting of hydrogen, lower alkyl, aryl, lower perhaloalkyl, and heteroaryl; $n_{13} = 0, 1, 2$, or 3; and

wherein i is 0, 1, 2, 3, 4;

- iii) an acyl of formula $-(X_1)_{n_1}-C(O)-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, heteroaryl, hydroxy, alkoxy, amino, and $-NH-X_3$,

where X_3 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, amino, and amide; and n_1 is 0, 1, 2 or 3; and

- iv) cyano;

- v) nitro;

- vi) an amino of formula $-(X_{15})_{n_{15}}-NX_{16}X_{17}$, where

X_{15} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_{16} and X_{17} , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_{15} is 0 or 1; and

- vii) a thioether or thiol of formula $-(X_{22})_{n_{22}}-S-X_{23}$, where


X_{22} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{23} is selected from the group consisting of hydrogen, lower alkyl, lower perfluoralkyl, aryl, and heteroaryl; and

n_{22} is 0, 1, 2, or 3 and

c) R_8 is selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) cyano;




wherein

X is selected from CH and nitrogen;

Y is selected from the group consisting of CH_2 , NH, oxygen and sulfur;

Z_1 and Z_2 are each independently selected from the group consisting of null, oxygen, sulfur, and $CR_{11}R_{12}$,

wherein R_{11} and R_{12} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy; and



wherein R_{13} and R_{14} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy;

- vi) optionally substituted acyl of the formula $-OC(O)R_E$, wherein $HOC(O)R_E$ is a pharmaceutically acceptable acid;

d) R_6 and R_7 are each independently selected from the group consisting of hydrogen and lower alkyl.

[0062] In certain embodiments, R₁₅ and R₁₆ are independently selected from the group consisting of an optionally substituted five-, six-, seven-, or eight- membered carbocyclic or heterocyclic ring, five-membered or six-membered heteroaryl ring, or six-membered aryl or heteroaryl ring.










[0063] In some embodiments, R₁₆ is selected from the group consisting of hydrogen, lower alkyl, and aryl.












[0064] In certain embodiments, the present invention relates to a compound of Formula II or III where T is sulfur. In other embodiments, T is oxygen, whereas in yet other embodiments, T is -NR.











[0065] In another aspect, the invention relates to a compound selected from the group consisting of the compounds set forth in Table 1, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof:











Table 1









Table 1

Comp'd No.	Structure
1	
2	
3	
4	
5	
6	
7	
8	
9	

10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	

21	
22	
23	
24	
25	
26	
27	
28	
29	
30	


31	
32	
33	
34	
35	
36	
37	
38	
39	
40	

41	
42	
43	
44	
45	
46	
47	
48	

[0066] In another aspect, the present invention is directed to a compound of Formula I, II, or III, as defined herein, including those in Table 1, where the compound is capable of inhibiting the catalytic activity of histone deacetylase (HDAC).


[0067] Another aspect of the present invention are compounds containing at least one thiol in a protected form, which can be released to provide a SH group prior to or simultaneous to use. Thiol moieties are known to be unstable in the presence of air and are oxidized to the corresponding disulfide. Protected thiol groups are those that can be converted under mild conditions into free thiol groups without other undesired side reactions taking place. Suitable thiol protecting groups include but are not limited to trityl (Trt), allyloxycarbonyl (Alloc), 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde), acetamidomethyl (Acm), t-butyl (tBu), or the like. Preferred thiol protecting groups include lower alkanoyl, e.g. acetyl. Free thiol, disulfides, and protected thiols are understood to be within the scope of this invention.

[0068] Another embodiment of the invention is compounds of Formula IV,



or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, or a pharmaceutical composition comprising such compounds and a pharmaceutically acceptable carrier, diluent or excipient, wherein

a) A is



wherein R_{18} is a lower alkyl, lower heteroalkyl, or five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

- i) optionally substituted $\text{C}_1\text{-C}_8$ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- ii) an alkoxy of formula $-(\text{X}_1)_{n1}-\text{O}-\text{X}_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl; and

n_1 is 0, 1, 2 or 3;

iii) halogen, partially halogenated alkyl, or perhaloalkyl;

iv) cyano;

v) nitro;

vi) an amino of formula $-(X_3)_{n_3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0 or 1;

vii) a thioether or thiol of formula $-(X_6)_{n_6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, perfluoroalkyl, aryl, and heteroaryl; and

n_6 is 0, 1, 2, or 3; and

viii) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$

X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;


X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, lower heteroalkyl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, lower heteroalkyl, and heteroaryl;

n_7 and n_9 are each independently is 0 or 1;

R' and R'' are each independently selected from the group consisting of hydrogen and lower alkyl;

Wherein R_{19} is H, C_{1-5} alkyl, or R_{19} taken together with R^1 forms a five-, six-, seven-, or eight-membered heterocyclic ring, o is 0, and the compound of formula IV has the following structure:



and W is independently selected from the group consisting of


- A) hydrogen;
- B) optionally substituted C_1-C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- C) optionally substituted aryl;
- D) optionally substituted heterocyclyl;
- E) an alkoxy of formula $-(X_{13})_{n_{13}}-O-X_{14}$, where

X_{13} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{14} is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl; $n_{13} = 0, 1, 2$, or 3; and

i is 0, 1, 2, 3, 4;


wherein R_{20} is H, C_{1-5} alkyl, or R_{20} taken together with R_{18} forms a five-, six-, seven-, or eight-membered heterocyclic ring, having the following structure:



b) wherein each R_1 is each independently selected from the group consisting of


- i) hydrogen;
- ii) lower alkyl;
- iii) lower alkylene;
- iv) halogen, partially halogenated alkyl, or perhaloalkyl;
- v) an alkoxy or perhaloalkoxy;

c) wherein [C] is



d) R_8 is selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) cyano;




wherein

X is selected from CH and nitrogen;

Y is selected from the group consisting of CH_2 , NH, oxygen and sulfur;

Z_1 and Z_2 are each independently selected from the group consisting of null, oxygen, sulfur, and $CR_{11}R_{12}$,

wherein R_{11} and R_{12} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy; and



wherein R_{13} and R_{14} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy;


- vi) optionally substituted acyl of the formula $-OC(O)R_E$, wherein $HOC(O)R_E$ is a pharmaceutically acceptable acid
- vii) or R_8 is equivalent to the balance of Formula IV to form a disulfide dimer;
- e) R_6 and R_7 are each independently selected from the group consisting of hydrogen and lower alkyl.

[0069] In another aspect are compounds having structural Formula IV wherein R_{19} and R_{20} are each independently H or C_{1-5} alkyl, and o and p are 0.

[0070] In another aspect are compounds having structural Formula IV wherein R_{18} is optionally substituted phenyl.

[0071] In another aspect are compounds having structural Formula IV wherein said R_8 forms a pharmaceutically acceptable acid upon thioester hydrolysis. Representative acids include N,N-diethylglycine; 4-ethylpiperazinoacetic acid; ethyl 2-methoxy-2-phenylacetic acid; N,N-dimethylglycine; (nitrophenoxysulfonyl)benzoic acid, acetic acid, maleic acid, fumaric acid, benzoic acid, tartronic acid, glutamic acid, aspartic acid, proline, D-amino acids, butyric acid, palmitic acid, stearic acid, oleic acid, pipercolic acid, phosphonic acid, phosphoric acid, pivalate (trimethylacetic acid), succinic acid, cinnamic acid, anthranilic acid, salicylic acid, lactic acid, and, pyruvic acids.

[0072] In another aspect are compounds having structural Formulae V or VI, VII, or VIII:




wherein

- a) R_6 and R_7 are each independently selected from the group consisting of hydrogen and lower alkyl;
- b) R_8 is selected from the group consisting of H, acyl, and heterocyclyl;

c) R_{22} is selected from the group consisting of C_{1-5} alkyl, C_{1-5} perhaloalkyl, C_{1-5} alkoxy, C_{1-5} perhaloalkyl alkoxy, and N-alkylamido;

d) $n = 0, 1, 2, 3$.

[0073] In another aspect are compounds having structural Formula:



and wherein R_{22} is C_{1-5} perfluoroalkyl and R_8 is a thiol protecting group as described herein.

[0074] In another aspect are compounds or compositions comprising compounds capable of inhibiting the catalytic activity of histone deacetylase (HDAC).

[0075] In some aspects of the invention, the disease to be treated by the methods of the present invention may be cancer. In some embodiments, but without limitation, the term cancer refers to and is selected from disorders such as colon cancer, breast cancer, ovarian cancer, lung cancer and prostate cancer, tumor invasion, tumor growth, tumor metastasis, and cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus, stomach, small intestine, large intestine, rectum, liver and biliary passages, pancreas, larynx, bone, connective tissue, skin, cervix uteri, corpus endometrium, testis, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and endocrine gland. The term "cancer" also encompasses Hodgkin's disease, non-Hodgkin's lymphomas, multiple myeloma and hematopoietic malignancies including leukemias (Chronic Lymphocytic Leukemia) and lymphomas including lymphocytic, granulocytic and monocytic.

[0076] Additional types of cancers which may be treated using the compounds and methods described herein include: adrenocarcinoma, angiosarcoma, astrocytoma, acoustic neuroma, anaplastic astrocytoma, basal cell carcinoma, blastoglioma, chondrosarcoma, choriocarcinoma, chordoma, craniopharyngioma, cutaneous melanoma, cystadenocarcinoma, endotheliosarcoma, embryonal carcinoma, ependymoma, Ewing's tumor, epithelial carcinoma, fibrosarcoma, gastric cancer, genitourinary tract cancers, glioblastoma multiforme, head and neck cancer, hemangioblastoma, hepatocellular carcinoma, hepatoma, Kaposi's sarcoma, large cell carcinoma, cancer of the larynx, leiomyosarcoma, leukemias, liposarcoma, lymphatic system cancer, lymphomas, lymphangiosarcoma, lymphangioendotheliosarcoma, medullary thyroid carcinoma,

medulloblastoma, meningioma mesothelioma, myelomas, myxosarcoma neuroblastoma, neurofibrosarcoma, oligodendroglioma, osteogenic sarcoma, epithelial ovarian cancer, papillary carcinoma, papillary adenocarcinomas, parathyroid tumours, pheochromocytoma, pinealoma, plasmacytomas, retinoblastoma, rhabdomyosarcoma, sebaceous gland carcinoma, seminoma, skin cancers, melanoma, small cell lung carcinoma, squamous cell carcinoma, sweat gland carcinoma, synovioma, thyroid cancer, uveal melanoma, and Wilm's tumor

[0077] In some aspects of the invention, the disease to be treated by the methods of the present invention may be a neurological or polyglutamine-repeat disorder. In some embodiments, but without limitation, the polyglutamine-repeat disorder is selected from Huntington's disease, Spinocerebellar ataxia 1 (SCA 1), Machado-Joseph disease (MJD)/Spinocerebellar ataxia 3 (SCA 3), Kennedy disease/Spinal and bulbar muscular atrophy (SBMA) and Dentatorubral pallidolusyan atrophy (DRPLA).

[0078] In some aspects of the invention, the disease to be treated by the methods of the present invention may be an anemias or thalassemia (such as Sickel Cell Disease (SCD). In some embodiments, but without limitation, the thalassemia is Sickel Cell Disease (SCD).

[0079] In some aspects of the invention, the disease to be treated by the methods of the present invention may be an inflammatory condition. In some embodiments, but without limitation, the inflammatory condition is selected from Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), ulcerative colitis and psoriasis.

[0080] In some aspects of the invention, the disease to be treated by the methods of the present invention may be an autoimmune disease. In some embodiments, but without limitation, the autoimmune disease is selected from Systemic Lupus Erythromatosus (SLE) and Multiple Sclerosis (MS).

[0081] In some aspects of the invention, the disease to be treated by the methods of the present invention may be a cardiovascular condition. In some embodiments, but without limitation, the cardiovascular condition is selected from cardiac hypertrophy and heart failure.

[0082] The terms "therapy" or "treating" as used herein refer to (1) reducing the rate of progress of a disease, or, in case of cancer reducing the size of the tumor; (2) inhibiting to some extent further progress of the disease, which in case of cancer may mean slowing to some extent, or preferably stopping, tumor metastasis or tumor growth; and/or, (3) relieving to some extent (or, preferably, eliminating) one or more symptoms associated with

the disease. Thus, the term "therapeutically effective amount" as used herein refers to that amount of the compound being administered which will provide therapy or affect treatment.

[0083] In some aspects of the invention, the compounds of the present invention are also anti-tumor compounds and/or inhibit the growth of a tumor, i.e., they are tumor-growth-inhibiting compounds. The terms "anti-tumor" and "tumor-growth-inhibiting," when modifying the term "compound," and the terms "inhibiting" and "reducing," when modifying the terms "compound" and/or "tumor," mean that the presence of the subject compound is correlated with at least the slowing of the rate of growth of the tumor. More preferably, the terms "anti-tumor," "tumor-growth-inhibiting," "inhibiting," and "reducing" refer to a correlation between the presence of the subject compound and at least the temporary cessation of tumor growth. The terms "anti-tumor," "tumor-growth-inhibiting," "inhibiting," and "reducing" also refer to, a correlation between the presence of the subject compound and at least the temporary reduction in the mass of the tumor.

[0084] The term "function" refers to the cellular role of HDAC. The term "catalytic activity", in the context of the invention, defines the rate at which HDAC deacetylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a product as a function of time. Deacetylation of a substrate occurs at the active-site of HDAC. The active-site is normally a cavity in which the substrate binds to HDAC and is deacetylated.

[0085] The term "substrate" as used herein refers to a molecule deacetylated by HDAC. The substrate is preferably a peptide and more preferably a protein. In some embodiments, the protein is a histone, whereas in other embodiments, the protein is not a histone.

[0086] The term "activates" refers to increasing the cellular function of HDAC. The term "inhibit" refers to decreasing the cellular function of HDAC. HDAC function is preferably the interaction with a natural binding partner and most preferably catalytic activity.

[0087] The term "modulates" refers to altering the function of HDAC by increasing or decreasing the probability that a complex forms between HDAC and a natural binding partner. A modulator may increase the probability that such a complex forms between HDAC and the natural binding partner, or may increase or decrease the probability that a complex forms between HDAC and the natural binding partner depending on the concentration of the compound exposed to HDAC, or may decrease the probability that a complex forms between HDAC and the natural binding partner. A modulator may activate

the catalytic activity of HDAC, or may activate or inhibit the catalytic activity of HDAC depending on the concentration of the compound exposed to HDAC, or may inhibit the catalytic activity of HDAC.

[0088] The term “complex” refers to an assembly of at least two molecules bound to one another. The term “natural binding partner” refers to polypeptides that bind to HDAC in cells. A change in the interaction between HDAC and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of HDAC/natural binding partner complex.

[0089] The term “contacting” as used herein refers to mixing a solution comprising a compound of the invention with a liquid medium bathing the cells of the methods. The solution comprising the compound may also comprise another component, such as dimethylsulfoxide (DMSO), which facilitates the uptake of the compound or compounds into the cells of the methods. The solution comprising the compound of the invention may be added to the medium bathing the cells by utilizing a delivery apparatus, such as a pipet-based device or syringe-based device.

[0090] The term “monitoring” refers to observing the effect of adding the compound to the cells of the method. The effect can be manifested in a change in cell phenotype, cell proliferation, HDAC catalytic activity, substrate protein acetylation levels, gene expression changes, or in the interaction between HDAC and a natural binding partner.

[0091] The term “effect” describes a change or an absence of a change in cell phenotype or cell proliferation. “Effect” can also describe a change or an absence of a change in the catalytic activity of HDAC. “Effect” can also describe a change or an absence of a change in an interaction between HDAC and a natural binding partner.

[0092] The term “cell phenotype” refers to the outward appearance of a cell or tissue or the function of the cell or tissue. Examples of cell phenotype are cell size (reduction or enlargement), cell proliferation (increased or decreased numbers of cells), cell differentiation (a change or absence of a change in cell shape), cell survival, apoptosis (cell death), or the utilization of a metabolic nutrient (e.g., glucose uptake). Changes or the absence of changes in cell phenotype are readily measured by techniques known in the art.

A. Pharmaceutical Compositions

[0093] The present invention also relates to a pharmaceutical composition comprising

- a) a compound of the invention, or a pharmaceutically acceptable salt, solvate, amide, ester, or prodrug thereof, as described herein; and

- b) a pharmaceutically acceptable carrier, diluent, or excipient, or a combination thereof.

[0094] The term "pharmaceutical composition" refers to a mixture of a compound of the invention with other chemical components, such as carriers, diluents or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to: intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

[0095] The term "carrier" refers to relatively nontoxic chemical compounds or agents. Such carriers may facilitate the incorporation of a compound into cells or tissues. For example, human serum albumin (HSA) is a commonly utilized carrier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism.

[0096] The term "diluent" refers to chemical compounds that are used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (providing pH control) are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline. It is a buffer found naturally in the blood system. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.

[0097] The compounds described herein can be administered to a human patient *per se*, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," 20th ed. Edited by Alfonso Gennaro, 2000.

1) Routes Of Administration

[0098] Suitable routes of administration may, for example, include oral, rectal, transmucosal, pulmonary, ophthalmic or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.

[0099] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in

a depot or sustained release formulation. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. The liposomes will be targeted to and taken up selectively by the organ.

2) Composition/Formulation

[00100] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

[00101] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; *e.g.*, in Remington's Pharmaceutical Sciences, above.

[00102] For intravenous injections, the agents of the invention may be formulated in aqueous solutions, preferably in pharmaceutically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For other parenteral injections, the agents of the invention may be formulated in aqueous or nonaqueous solutions, preferably with pharmaceutically compatible buffers or excipients. Such excipients are generally known in the art.

[00103] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers or excipients well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipient with one or more compound of the invention, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose,

hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents may be added, such as the cross-linked croscarmellose sodium, polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[00104] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[00105] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

[00106] For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in conventional manner.

[00107] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[00108] The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[00109] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[00110] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

[00111] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

[00112] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[00113] A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be a 10% ethanol, 10% polyethylene glycol 300, 10% polyethylene glycol 40 castor oil (PEG-40 castor oil) with 70% aqueous solution. This cosolvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a cosolvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the cosolvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of PEG-40 castor oil, the fraction size of polyethylene glycol 300 may be varied; other biocompatible polymers may replace polyethylene glycol, *e.g.*, polyvinyl pyrrolidone; and other sugars or polysaccharides may be included in the aqueous solution.

[00114] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of


delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as N-methylpyrrolidone also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

[00115] Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, *etc.* Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free acid or base forms.

EXAMPLES

[00116] The examples below are non-limiting and are merely representative of various aspects of the invention.


Example 1: General Procedure for the Synthesis of Thiocyanates:



Reagents: (a) NaSCN, EtOH

[00117] Sodium thiocyanide (1 eq.) is dissolved in ethanol (9 mL) before the α -bromo ketone (1 eq.) is added as a solid. The resulting solution is then allowed to stir at room temperature for 10 minutes. The volatiles are removed under a stream of nitrogen and the resulting residue is taken up in ethyl acetate before being extracted with water. The organic fraction is dried over Na_2SO_4 and evaporated to leave an oil which is crystallized upon standing. The product is purified by radial chromatography and recrystallized from EtOAc/hexanes.

This general procedure was utilized for the preparation of Compounds 1-13, and is specifically exemplified for Compound 1, below:



Compound 1


Compound 1: Synthesis of 1-Phenyl-2-thiocyanato-ethanone:

[00118] Sodium thiocyanide (200 mg, 2.47 mmol) was dissolved in ethanol (9 mL) before 1-bromoacetophenone (481 mg, 2.42 mmol) was added as a solid. The resulting tan solution was then allowed to stir at room temperature for 10 minutes. The volatiles were removed under a stream of nitrogen and the resulting residue was taken up in ethyl acetate before being extracted with water. The organic fraction was dried over Na_2SO_4 and evaporated to leave an oil which crystallized upon standing. The product, Compound 1 was

purified by radial chromatography and recrystallized from EtOAc/hexanes (400 mg, 2.26 mmol, 93 %). It had $^1\text{H-NMR}$: (CDCl_3) 7.94 (dd, 2H), 7.66 (m, 1H), 7.56 (m, 2H), 4.75 (s, 2H) ppm. It had LCMS (ES $^+$): 91 $[\text{M} - \text{C}_2\text{NOS}]^+$ m/e.

Compounds 2-13 were similarly prepared.


Example 2: General Procedure for the Synthesis of Thiazolines:



Reagents: (a) 2-mercaptothiazoline, NaOH, EtOH

[00119] 2-Mercaptothiazoline (1 eq.) is suspended in ethanol (7 mL) before NaOH (1.8 mL, 2 M) is added affording a clear solution. The alpha-bromo ketone compound (1 eq.) is then added as a solid and the resulting solution is allowed to stir at 40 °C for 3 hours. The volatiles are then removed under a stream of nitrogen before water and EtOAc are added for extraction. The organic layer is dried over Na_2SO_4 and evaporated to leave a dark residue which is purified by radial chromatography. The product is recrystallized from EtOAc/hexanes.

[00120] This general procedure was utilized for the preparation of Compounds 14-31, and is specifically exemplified for Compound 14, with analytical data in support of characterization of Compounds 26, 27, 28 and 29, below:




Compound 14

Compound 14: Synthesis of 2-(4,5-Dihydro-thiazol-2-ylsulfanyl)-1-phenyl-ethanone:

[00121] 2-Mercaptothiazoline (300 mg, 2.5 mmol) was suspended in ethanol (7 mL) before NaOH (1.8 mL, 2 M) was added affording a clear solution. 1-Bromoacetophenone (491 mg, 2.47 mmol) was then added as a solid and the resulting red solution was allowed to


stir at 40 °C for 3 hours. The volatiles were then removed under a stream of nitrogen before water and EtOAc were added for extraction. The organic layer was dried over Na₂SO₄ and evaporated to leave a dark residue which was purified by radial chromatography. The purified product, Compound 14, was recrystallized from EtOAc/hexanes (500 mg, 84 %). It had ¹H-NMR: (CDCl₃) 8.01 (m, 2H), 7.60 (m, 1H), 7.48 (m, 2H), 4.69 (s, 2H), 4.18 (t, 2H), 3.43 (t, 2H) ppm. It had LCMS (ES⁺): 238 [MH]⁺ m/e.



Compound 26

Compound 26: Characterization of N-{4-[2-(4,5-Dihydro-thiazol-2-ylsulfanyl)-acetyl]-phenyl}-3,4-dimethoxy-benzenesulfonamide


[00122] ¹H-NMR: (DMSO-d₆) 10.75 (s, 1H), 7.88 (d, 2H), 7.50 (d, 1H), 7.31 (d, 1H), 7.23 (d, 2H), 7.08 (d, 1H), 4.70 (s, 2H), 4.04 (t, 2H), 3.79 (s, 3H), 3.77 (s, 3H), 3.43 (t, 2H) ppm. It had LC-MS (ES⁺): 453 [M]⁺ m/e.



Compound 27


Compound 27: Characterization of N-{4-[2-(4,5-Dihydro-thiazol-2-ylsulfanyl)-acetyl]-phenyl}-4-trifluoromethoxy-benzenesulfonamide

[00123] ¹H-NMR: (CDCl₃) 7.91 (d, 2H), 7.88 (d, 2H), 7.29 (d, 2H), 7.17 (d, 2H), 6.71 (bs, 1H), 4.59 (s, 2H), 4.16 (t, 2H), 3.43 (t, 2H) ppm. It had LC-MS (ES⁺): 477 [M]⁺ m/e.



Compound 28: Characterization of N-(4-{3-[2-(4,5-Dihydro-thiazol-2-ylsulfanyl)-acetyl]-phenylsulfamoyl}-phenyl)-acetamide

[00124] $^1\text{H-NMR}$: (DMSO- d_6) 10.40 (bs, 1H), 10.30 (bs, 1H), 7.70 (m, 6H), 7.30 (m, 2H), 4.70 (s, 1H), 4.1 (t, 2H), 3.50 (t, 2H), 2.00 (s, 3H) ppm. It had LC-MS (ES $^+$): 450 $[\text{M}]^+$ m/e.




Compound 29: Characterization of N-(4-{4-[2-(4,5-Dihydro-thiazol-2-ylsulfanyl)-acetyl]-phenylsulfamoyl}-phenyl)-acetamide

[00125] $^1\text{H-NMR}$: (DMSO- d_6) 10.80 (bs, 1H), 10.30 (bs, 1H), 7.86 (d, 2H), 7.76 (m, 4H), 7.19 (d, 2H), 4.69 (s, 2H), 4.03 (t, 2H), 3.42 (t, 2H), 2.05 (s, 3H) ppm. It had LC-MS (ES $^+$): 450 $[\text{M}]^+$ m/e.

Compounds 15-25, 30 and 31 were similarly prepared.


Example 3: General Procedure for the Synthesis of Thiazolinones:



[00126] Rhodanine (1.0 eq.) is dissolved in EtOH (2 mL) and 2 M NaOH (0.275 mL) with vigorous stirring. Once the Rhodanine is completely dissolved, the alpha-

bromo ketone compound (1 eq.) is added with constant stirring. The reaction is mixed overnight at 40°C. After 18 hrs the reaction is removed from the heat and left stirring at room temp for 48 hrs. The resulting reaction mixture is then diluted with water (5 mL) and extracted with dichloromethane (3 x 5 ml). The organic layer is dried over Na₂SO₄ and then evaporated to yield an oil. The oil is purified by chromatotron using a 50/50 mixture of ethyl acetate in hexanes as the mobile phase. The purified product is then recrystallized in hexanes to complete its purification.

[00127] This general procedure was utilized for the preparation of Compounds 32-35, and is specifically exemplified for Compounds 34, below:




Compound 34: Synthesis of 2-[2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-oxo-ethylsulfanyl]-thiazol-4-one:

[00128] Rhodanine (0.052 g, 0.388 mmol, 1.0 eq.) was dissolved in EtOH (2ml) and 2 M NaOH (0.275 ml, 0.550 mmol, 1.42 eq.) with vigorous stirring. Once the Rhodanine was completely dissolved, 6-Chloroacetyl-1,4-benzodioxane (0.080 g, 0.380 mmol, 0.98 eq.) was added with constant stirring. (It should be noted that α -chloro ketones were used when the corresponding α -bromo ketones were not available.) The reaction was mixed overnight at 40°C. After 18 hrs the reaction was removed from the heat and left stirring at room temp for 48 hrs. The resulting reaction mixture was then diluted with water (5 ml) and extracted with dichloromethane (3 x 5 ml). The organic layer was dried over Na₂SO₄ and then evaporated to yield an oil. The oil was purified by chromatotron using a 50/50 mixture of ethyl acetate in hexanes as the mobile phase. The purified product, Compound 34, was then recrystallized in hexanes to complete its purification (20mg, 0.0646mmol, 17%). The product was characterized by ¹H-NMR: (CDCl₃) 7.55 (q, 2H), 6.93 (d, 1H), 4.93 (s, 2H), 4.31 (m, 4H), 4.02 (s, 2H) ppm. In addition LCMS [ES⁺] analysis yielded a single peak, 310 [M]⁺ m/e.

Compounds 32, 33 and 35 were similarly prepared.

Example 4: General Procedure for the Synthesis of Mercaptans and Disulfides:


Schemes 1a illustrates the general synthesis of disulfide embodiments of the present invention.

Scheme 1a

Reagents: (a) KSC(O)CH₃, MeOH; (b) NaOH, MeOH

Scheme 1b depicts an alternative general scheme for the synthesis of thiol (mercaptan) and disulfide embodiments of the present invention


Scheme 1b



Reagents: (a) PTT, THF; (b) N-methyl 2-thiopyridone, EtOH;
(c) NaOH, water; (d) MeOH, water.


Scheme 1c depicts the synthesis of Compound 47, and is exemplary of the general applicability of scheme 1a and 1b to specific α -thio ketone and disulfide molecular embodiments of the invention.

Scheme 1c




Reagents: (a) pyridine, THF; (b) PTT, THF; (c) N-methyl 2-thiopyridone, EtOH; (d) NaOH, water; (e) MeOH, water.

Compound 47: Synthesis of Thioacetic acid *S*-{2-oxo-2-[4-(4-trifluoromethoxybenzenesulfonylamino)-phenyl]-ethyl} disulfide
[00129]




Compound 47

Step 1: Synthesis of Intermediate A

Intermediate A

Intermediate A: Synthesis of N-(4-Acetyl-phenyl)-4-trifluoromethoxy-benzenesulfonamide


4'-Amino acetophenone (0.375 g, 2.78 mmol) was dissolved in THF (5 ml) before pyridine (0.674 ml, 8.34 mmol) was added, leaving a yellow solution. 4-trifluoromethoxy benzenesulfonylchloride (0.871 g, 3.34 mmol) was then added dropwise with stirring. After removal of THF and pyridine, the desired sulfonamide (0.848 g, 2.36 mmol, 85 %) was recrystallized from ethyl acetate and hexanes. ¹H-NMR: (400 MHz, CDCl₃) 7.89 (m, 4H), 7.29 (d, 1H), 7.16 (d, 2H), 6.88 (s, 1H), 2.55 (s, 3H). LC-MS (ES⁺): 360 [MH]⁺ m/e.

Step 2: Synthesis of Intermediate B

Intermediate B

Intermediate B: Synthesis of N-[4-(2-Bromo-acetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide


Intermediate A (0.32 g, 0.868 mmol) was dissolved in THF (9 ml), and phenyltrimethylammonium tribromide (PTT) (0.368 g, 0.868 mmol) was added as a solid leaving an orange solution which began to deposit a white solid immediately. Stirring for 1.5 hours leaves a colorless mixture to which water (5 ml) was added. THF was then evaporated and the resulting aqueous mixture was extracted with ethyl acetate. Drying over Na₂SO₄ and evaporation leaves a white crystalline solid (90% desired mono-brominated material by LC-MS, 5% starting material, 5 % dibrominated) suitable for the next step. LC-MS (ES⁻): 436, 438 m/e.

Step 3: Synthesis of Intermediate C


Intermediate C

Intermediate C: Synthesis of 1-Methyl-2-{2-oxo-2-[4-(4-trifluoromethoxybenzenesulphonylamino)phenyl]ethylsulfanyl}-pyridinium bromide

Intermediate B (0.141 g crude material, 0.322 mmol) was dissolved in ethanol (2 ml) before N-methyl thiopyridone (0.040 g, 0.322 mmol) was added as a solid. The resulting yellow solution was then heated to reflux overnight. Evaporation of the volatiles leaves a residue (75 % by NMR, 0.116 g, 0.240 mmol) suitable for the next step, however, the product may be recrystallized from ethanol if desired. ¹H-NMR: (400 MHz, DMSO-d₆) 11.21 (s, 1H), 8.90 (d, 1H), 8.18 (t, 1H), 8.03 (m, 5H), 7.90 (t, 1H), 7.80 (d, 2H), 7.15 (d, 2H), 5.33 (s, 2H), 4.24 (s, 3H). LC-MS (ES⁺): 483 [M]⁺ m/e.

Steps 4 and 5: Synthesis of Compound 43 and Compound 47

Compound 43



Compound 47


[00130] Compound 43 and Compound 47: Synthesis of N-[4-(2-Mercaptoacetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide (43) and corresponding disulfide (47)

Intermediate C (4.35 g, 7.72 mmol) was suspended in water (1.7 l) before 2 M NaOH (7.25 ml) was added. Solid NaOH (1 g) was then added, and the resulting mixture was then heated to reflux overnight, producing a red solution. The solution was then acidified to a pH of 1 and extracted with ethyl acetate. Drying over Na₂SO₄ and evaporation leaves a red oil.

Throughout the work-up, the alpha-mercapto ketone readily oxidizes to the corresponding disulfide (47), which was purified by preparative HPLC (0.582 g, 0.75 mmol, 10 %). ¹H-NMR: (400 MHz, DMSO-d₆) 11.09 (bs, 2H), 7.97 (d, 4H), 7.85 (d, 4H), 7.57 (d, 4H), 7.22 (d, 4H), 4.29 (s, 4H). LC-MS (ES⁺): 781 [MH]⁺ m/e.

[00131] Alpha thioketones Compounds 36-42 and disulfide Compounds 44-46 were similarly prepared.


[00132] Analytical data in support of the characterization of Compound 36-41 and Compounds 44-46 are presented below:



Compound 36

Compound 36: Characterization of 2-Mercapto-1-phenyl-ethanone


[00133] ¹H-NMR: (400 MHz, CDCl₃) 7.99 (d, 2H), 7.61 (m, 1H), 7.51 (m, 2H), 3.97 (d, 2H), 2.14 (t, 1H). LC-MS (ES⁺): 153 [MH]⁺ m/e.



Compound 37

Compound 37: Characterization of 1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-mercapto-ethanone


[00134] ¹H-NMR: (400 MHz, CDCl₃) 7.50 (m, 2H), 6.93 (dd, 1H), 4.31 (m, 4H), 3.88 (d, 2H), 2.13 (t, 1H). LC-MS (ES⁺): 211 [MH]⁺ m/e.



Compound 38

Compound 38: Characterization of N-[4-(2-Mercapto-acetyl)-phenyl]-acetamide


[00135] ¹H-NMR: (400 MHz, DMSO-d₆) 10.32 (bs, 1H), 7.95 (d, 2H), 7.72 (d, 2H), 4.02 (d, 2H), 2.84 (t, 1H), 2.09 (s, 3H). LC-MS (ES⁺): 210 [MH]⁺ m/e



Compound 39

Compound 39: Characteriation of 1-(3,4-Dimethoxy-phenyl)-2-mercapto-ethanone


[00136] $^1\text{H-NMR}$: (400 MHz, CDCl_3) 7.56 (m, 2H), 6.91 (d, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.92 (d, 2H), 2.15 (t, 1H). LC-MS (ES⁺): 213 $[\text{MH}]^+$ m/e.



Compound 40

Compound 40: Characterization of 1-(4-Diethylamino-phenyl)-2-mercapto-ethanone


[00137] $^1\text{H-NMR}$: (400 MHz, CDCl_3) 7.83 (dd, 2H), 6.63 (dd, 2H), 3.85 (d, 2H), 3.43 (q, 4H), 2.17 (t, 1H), 1.21 (t, 6H). LC-MS (ES⁺): 224 $[\text{MH}]^+$ m/e.



Compound 41

Compound 41: Characterization of 1-(4-Bromo-phenyl)-2-mercapto-ethanone


[00138] $^1\text{H-NMR}$: (400 MHz, CDCl_3) 7.83 (m, 2H), 7.64 (m, 2H), 3.92 (d, 2H), 2.11 (t, 1H). LC-MS (ES⁺): 230, 232 $[\text{MH}]^+$ m/e.



Compound 44

Compound 44: Synthesis of 2-(2-Oxo-2-phenyl-ethyl)-disulfany-1-phenyl-ethanone


[00139] $^1\text{H-NMR}$: (400 MHz, CDCl_3) 7.95 (d, 4H), 7.61 (t, 2H), 7.49 (t, 4H), 4.22 (s, 4H). LC-MS (ES+): 303 $[\text{MH}]^+$ m/e.



Compound 45

Compound 45: Synthesis of 1-(3,4-Dichloro-phenyl)-2-[2-(3,4-dichloro-phenyl)-2-oxo-ethyl]disulfanylanthione

[00140] $^1\text{H-NMR}$: (400 MHz, CDCl_3) 8.03 (d, 2H), 7.76 (dd, 2H), 7.56 (d, 2H), 4.13 (s, 4H), 7.22 (d, 4H), 4.29 (s, 4H). LC-MS (ES+): 436 $[\text{MH}]^+$ m/e.



Compound 46


Compound 46: Synthesis of 1-(3,4-Dimethoxy-phenyl)-2-[2-(3,4-dimethoxy-phenyl)-2-oxo-ethyl]disulfanylanthione

[00141] $^1\text{H-NMR}$: (400 MHz, CDCl_3) 7.55 (m, 4H), 6.87 (d, 2H), 4.15 (s, 4H), 3.95 (s, 6H), 3.94 (s, 6H). LC-MS (ES+): 423 $[\text{MH}]^+$ m/e.


Example 5: General Procedure for the Synthesis of Thioesters and an Alternate General Synthesis of Disulfides:

Scheme 2 outlines a general synthesis of thioesters, explicitly exemplified with reference to the preparation of Compound 48. Hydrolysis of thioesters, followed by oxidation, results in a general synthesis of disulfides, explicitly exemplified with reference to the preparation of Compound 47.

Scheme 2




Reagents: a) MeOH, potassium thioacetate



Compound 48

Compound 48: Thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxybenzenesulfonylamino)phenyl]-ethyl} ester

[00142] Intermediate B (29 g crude material, 66.18 mmol) was dissolved in methanol (500 ml) before potassium thioacetate (8.23 g, 72.06 mmol) was added as a solid. LC-MS of the resulting yellow solution shows the reaction is complete in minutes. Evaporation of the volatiles leaves a tan residue which was taken up into dichloromethane (100 ml), during which a deposit of disulfide (thioacetic acid) was deposited and filtered. The desired thioester could then be recrystallized from dichloromethane/hexanes (18.52 g, 42.67 mmol, 64 %) It had $^1\text{H-NMR}$: (DMSO- d_6) 11.09 (bs, 1H), 7.98 (d, 2H), 7.92 (d, 2H), 7.59 (d, 2H), 7.24 (d, 2H), 4.42 (s, 2H), 2.36 (s, 3H) ppm. It had LC-MS (ES $^+$): 434 $[\text{M}]^+$ m/e.



Compound 47

[00143] **Compound 47:** Corresponding disulfide of Compound 43

[00144] Compound 48 (2.3 g, 5.3 mmol) was dissolved in MeOH (50 ml) before solid NaOH was carefully added with vigorous stirring. The resulting yellow solution was then stirred for 2 hours before being neutralized with con. HCl and evaporated to leave a red residue. Water (20 ml) was added and the mixture extracted with EtOAc. The organic

fractions were dried over Na₂SO₄ and evaporated. The residue was taken up in CH₂Cl₂ (50 ml) and stirred while open to the air. The desired disulfide precipitates within hours and is complete overnight yielding a pure solid (1.1 g, 1.41 mmol, 53 %). It had identical spectral characteristics as the material obtained in the original synthesis.

Example 9: Inhibition Assays:

In vitro HDAC-inhibition Assay:

[00145] This assay measures a compound's ability to inhibit acetyl-lysine deacetylation *in vitro* and was used as both a primary screening method as well as for IC₅₀ determinations of confirmed inhibitors. The assay is performed *in vitro* using an HDAC enzyme source (e.g. partially purified nuclear extract or immunopurified HDAC complexes) and a proprietary fluorescent substrate / developer system (HDAC Quantizyme *Fluor de Lys* Fluorescent Activity Assay, BIOMOL). The assay is run in 1,536-well Greiner white-bottom plates using the following volumes and order of addition:

[00146] Step 1: Enzyme (2.5 ul) source added to plate (from refrigerated container)

Step 2: Compounds (50 nl) added with pin transfer device

Step 3: *Fluor de Lys* (2.5 ul) substrate added, incubate at RT, 30 minutes

Step 4: Developer (5 ul) solution is added (containing TSA), to stop reaction

Step 5: Plate Reader - data collection

[00147] The deacetylated fluorophore is excited with 360 nm light and the emitted light (460 nm) is detected on an automated fluorometric plate reader (Aquest, Molecular Devices).

Cellular Histone Hyperacetylation Assays:

[00148] These two secondary assays evaluates a compound's ability to inhibit HDAC in cells by measuring cellular histone acetylation levels. The cytoblot facilitates quantitative EC₅₀ information for cellular HDAC inhibition. Transformed cell lines (e.g. HeLa, A549, MCF-7) are cultured under standard media and culture conditions prior to plating.

For Cytoblot:

[00149] Cells (approx. 2,500/well) are allowed to adhere 10-24 hours to wells of a 384-well Greiner PS assay plate in media containing 1-5% serum. Cells are treated with appropriate compound and specific concentrations for 0 to 24 hours. Cells are washed once with PBS (60 ul) and then fixed (95% ethanol, 5% acetic acid or 2% PFA) for 1 minute at RT (30 ul). Cells are blocked with 1% BSA for 1 hour and washed and stained with antibody (e.g. anti-Acetylated Histone H3, *Upstate Biotechnology*), followed by washing and incubation with an appropriate secondary antibody conjugated to HRP or fluorophore. For luminescence assays, signal is generated using Luminol substrate (*Santa Cruz Biotechnology*) and detected using an Aquest plate reader (*Molecular Devices*).

For Immunoblot:

[00150] Cells (4×10^5 /well) are plated into Corning 6-well dish and allowed to adhere overnight. Cells are treated with compound at appropriate concentration for 12-18 hours at 37 degrees. Cells are washed with PBS on ice. Cells are dislodged with rubber policeman and lysed in buffer containing 25 mM Tris, pH7.6; 150 mM NaCl, 25 mM MgCl₂, 1% Tween-20, and nuclei collected by centrifugation (7500g). Nuclei are washed once in 25 mM Tris, pH7.6; 10 mM EDTA, collected by centrifugation (7500g). Supernatant is removed and histones are extracted using 0.4 M HCl. Samples are centrifuged at 14000g and supernatants are precipitated in 1 ml cold acetone. The histone pellet is dissolved in water and histones are separated and analyzed by SDS-PAGE Coomassie and immunoblotting (anti-acetylated histone antibodies, *Upstate Biotechnology*) using standard techniques.

Differential Cytotoxicity Assay:

[00151] HDAC inhibitors display differential cytotoxicity toward certain transformed cell lines. Cells are cultured according to standard ATCC recommended conditions that are appropriate to each cell type. Compounds were tested for their ability to kill different cell types (normal and transformed) using the ATPlite luminescence ATP detection assay system (*Perkin Elmer*). Assays are run in either 384-well or 1536-well Greiner PS plates. Cells (30 ul or 5 ul, respectively) are dispensed using either multichannel pipette for 384-well plates, or proprietary *Kalypsys* bulk liquid dispenser for 1536-well plates. Compounds added using proprietary pin-transfer device (500 nL or 5 nL) and incubated 5 to 30 hours prior to analysis. Luminescence is measured using Aquest plate reader (*Molecular Devices*).

[00152] The activity of some of the compounds of the invention are shown in Table 2, below, together with data for positive controls: TSA, HC-toxin, Dioxothiophene & MS-275.











Table 2













Compound Description	in vitro IC ₅₀ (μ M)	% Max Inhibition (in vitro)	Cellular IC ₅₀ (μ M)	% Max Inhibition (cellular)
TSA positive control (published in vitro IC ₅₀ = 3 - 6 nM)	<1	100	<1	100
HC-toxin positive control (published in vitro IC ₅₀ = 7-10 nM)	<1	>75	N.D.	N.D.
Dioxothiophene*	>10	<50	N.D.	N.D.
MS-275 (clinical compound - benzamide anilide)	>10	>50	1-10	>75
1	1-10	>75	active	N.D.
2	<1	>75	active	N.D.
3	<1	>75	1-10	104
4	<1	>75	1-10	>75
5	<1	>75	active	N.D.
6	<1	>75	1-10	>75
7	<1	>75	1-10	>75
8	<1	>75	active	N.D.
9	<1	>75	active	N.D.
10	1-10	>75	active	N.D.
11	1-10	>50	active	N.D.
12	1-10	>75	N.D.	N.D.
13	1-10	>75	active	N.D.
14	>10	>75	>10	<50
15	1-10	>75	1-10	>75
16	1-10	>75	active	N.D.
17	>10	>75	active	N.D.
18	>10	>75	active	N.D.
19	>10	>75	1-10	>50
20	>10	>75	active	N.D.
21	>10	>75	1-10	>75
22	>10	<50	1-10	<50
23	>10	>50	active	N.D.
24	>10	>50	active	N.D.
25	>10	<50	active	N.D.
26	1-10	>75	<1	>75
27	1-10	>75	1-10	>75
29	1-10	>75	1-10	>75
30	1-10	>75	1-10	>75
31	1-10	>75	1-10	>75
32	<1	>75	>10	>50
33	<1	>75	>10	>75
34	<1	>75	1-10	>75
41	<1	>75	active	>75
42	1-10	>75	>10	>75















Compound Description	in vitro IC ₅₀ (μ M)	% Max Inhibition (in vitro)	Cellular IC ₅₀ (μ M)	% Max. Inhibition (cellular)
47	<1	>75	<1	>75
48	<1	>75	<1	>75

"N.D." indicates not determined because max inhibition was not reached at highest concentration tested. "Active" means the compound showed inhibitory activity but the cellular IC₅₀ could not be determined

[00153] Exemplary compounds and pharmaceutically acceptable esters or prodrugs thereof according to the invention include, but are not limited to, illustrative disulfide dimers, mercaptans, and thioesters as shown herein. Exemplary mercaptans of compounds according to structures I, II, or IV include the following:






















[00154] Preferred disulfides are symmetric and in a preferred embodiment, compounds of structure III are provided by the invention wherein T=S, all R₆ are equivalent, all R₇ are equivalent, and R₁₅=R₁₆ or compounds of structure IV wherein R₈ is defined so



as to form a symmetric disulfide dimer. Exemplary disulfides according to structures I, III, and IV include the following:










































[00155] Preferred thioesters of the invention include compounds of structures I, II, and IV wherein thioester hydrolysis yields an organic acid which is pharmaceutically acceptable including, but not limited to the following exemplary thioesters:










WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient and a compound having structural formula I,



or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof,
wherein

- a) R_1 - R_5 is each independently selected from the group consisting of
- i) hydrogen;
 - ii) lower alkyl;
 - iii) halogen or perhaloalkyl;
 - iv) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where
 - X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl; and
 - $n1$ is 0, 1, 2 or 3; and
 - v) a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of
 - A) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
 - B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where
 - X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, lower perfluoroalkyl, and heteroaryl; and
 - $n1$ is 0, 1, 2, or 3;

- C) halogen or lower perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where
 X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and
 $n3$ is 0, 1, 2, or 3;
- G) a thioether or thiol of formula $-(X_6)_{n6}-S-X_7$, where
 X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_7 is selected from the group consisting of hydrogen, lower alkyl, aryl, lower perfluoroalkyl and heteroaryl; and
 $n6$ is 0, 1, 2, or 3; and
- H) an amide of formula $-(X_7)_{n7}-NH-C(O)-X_8$ or $-(X_9)_{n9}-C(O)-NH-X_{10}$
 X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and
 X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, heteroalkyl, aryl, and heteroaryl;
 $n7$ and $n9$ are each independently is 0 or 1;

- vi) an acyl of formula $-(X_1)_{n1}-C(O)-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, perfluoroalkyl, heteroaryl, hydroxy, alkoxy, amino, and $-NH-X_3$,

where X_3 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, amino, and amide; and

$n1$ is 0, 1, 2, or 3; and

- vii) cyano;

- viii) nitro;

- ix) an amino of formula $-(X_{15})_{n15}-NX_{16}X_{17}$, where

X_{15} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_{16} and X_{17} , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

$n15$ is 0 or 1;


- x) a thioether or thiol of formula $-(X_{22})_{n22}-S-X_{23}$, where

X_{22} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{23} is selected from the group consisting of hydrogen, lower alkyl, perfluoroalkyl, aryl, and heteroaryl; and

$n22$ is 0, 1, 2, or 3;

- xi) an N-sulfonamido of structure



wherein

R₁₈ is a lower alkyl, lower heteroalkyl, or is a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

- A) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- B) an alkoxy of formula -(X₁)_{n1}-O-X₂, where
 - X₁ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₂ is selected from the group consisting of hydrogen, lower alkyl, perhaloalkyl, aryl, and heteroaryl; and
 - n₁ is 0, 1, 2, or 3;
- C) halogen or perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula -(X₃)_{n3}-NX₄X₅, where
 - X₃ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₄ and X₅ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X₄ and X₅, taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and
 - n₃ is 0, or 1;
- G) a thioether or thiol of formula -(X₆)_{n6}-S-X₇, where
 - X₆ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₇ is selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl, perfluoroalkyl; and
 - n₆ is 0, 1, 2, or 3; and

- H) an amide of formula $-(X_7)_{n7}-NH-C(O)-X_8$ or $-(X_9)_{n9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, heteroaryl, heteroalkyl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, aryl, and heteroaryl, and heteroalkyl;


n_7 and n_9 are each independently is 0 or 1;

R_{20} is H, lower alkyl, lower aralkyl, or R_{20} taken together with R_{18} forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, having the following structure:



i is 0, 1, 2, 3, 4;

- xii) an S-sulfonamido of formula



wherein R_{18} is a lower alkyl, lower heteroalkyl, or a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

- A) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where
 - X₁ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₂ is selected from the group consisting of hydrogen, lower alkyl, aryl, perhaloalkyl, and heteroaryl; and
 - n₁ is 0, 1, 2 or 3;
- C) halogen or perhaloalkyl;
- D) cyano;
- E) nitro;
- F) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where
 - X₃ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₄ and X₅ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X₄ and X₅, taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and
 - n₃ is 0 or 1;
- G) a thioether or thiol of formula $-(X_6)_{n6}-S-X_7$, where
 - X₆ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 - X₇ is selected from the group consisting of hydrogen, lower alkyl, aryl, perfluoroalkyl, and heteroaryl; and
 - n₆ is 0, 1, 2, or 3;
- H) an amide of formula $-(X_7)_{n7}-NH-C(O)-X_8$ or $-(X_9)_{n9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower heteroalkyl, lower alkenyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower heteroalkyl, lower alkenyl, aryl, and heteroaryl;

n_7 and n_9 are each independently is 0 or 1;

R_{19} is H, C_{1-5} alkyl, C_{1-5} aralkyl, or taken together with one of R_1 , R_2 , R_3 , R_4 , or R_5 , said R_{19} forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, having the following structure:



wherein i is 0, 1, 2, 3, 4;

or R_1 and R_2 , taken together along with the two ring carbons to which they are attached, or R_2 and R_3 , taken together along with the two ring carbons to which they are attached, or R_3 and R_4 , taken together along with the two ring carbons to which they are attached, or R_4 and R_5 , taken together along with the two ring carbons to which they are attached, form a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a six-membered aromatic or heteroaromatic, or a five- or six-membered heteroaromatic ring, each of which is optionally substituted with one or more substituents, W ;

wherein each W is independently selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) optionally substituted aryl;
- iv) optionally substituted heterocyclyl;

- v) an alkoxy of formula $-(X_{13})_{n13}-O-X_{14}$, where

X_{13} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{14} is selected from the group consisting of hydrogen, lower alkyl, perhaloalkyl, aryl, and heteroaryl; and

$n13$ is 0, 1, 2, or 3;

- vi) halogen or perhaloalkyl;

- vii) cyano;

- viii) nitro;

- ix) an amino of formula $-(X_{15})_{n15}-NX_{16}X_{17}$, where

X_{15} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_{16} and X_{17} , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

$n15$ is 0, 1, 2, or 3; and


- x) a thioether or thiol of formula $-(X_{22})_{n22}-S-X_{23}$, where

X_{22} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{23} is selected from the group consisting of hydrogen, lower alkyl, perfluoroalkyl, aryl, and heteroaryl; and


$n22$ is 0, 1, 2, or 3;

- xi) an S-sulfonamido of formula



wherein X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, lower heteroalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

- xii) an N-sulfonamido of structure




wherein X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, lower heteroalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

- b) R_6 and R_7 are each independently selected from the group consisting of hydrogen and lower alkyl;

- c) R_8 is selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) cyano;




wherein

X is selected from CH and nitrogen;

Y is selected from the group consisting of CH_2 , NH, oxygen and sulfur;

Z_1 and Z_2 are each independently selected from the group consisting of null, oxygen, sulfur, and $CR_{11}R_{12}$,




wherein R_{11} and R_{12} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy; and



wherein R_{13} and R_{14} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy;


- vi) optionally substituted acyl of the formula $-C(O)R_E$, wherein $HOC(O)R_E$ is any pharmaceutically acceptable acid;
- vii) or R_8 is equivalent to the balance of Formula I to form a disulfide dimer;
- d) Q is selected from the group consisting of a bond, oxygen, sulfur, $-(CH_2)_m-$, $-(CH_2)_mNH-$, $-(CH_2)_m(CO)-$, $-(CH_2)_mNH(CO)-$, and $-(CH_2)_mC(O)NH-$, wherein m is 0-7, wherein if Q is not symmetric, Q may be attached in either order; and
- e) T is selected from the group consisting of oxygen, sulfur, and $-NR_{17}$, wherein R_{17} is selected from the group consisting of hydrogen, lower alkyl, and aryl.

2. The composition of Claim 1, wherein R_1 - R_5 are hydrogen.
3. The composition of Claim 1, wherein R_2 is an alkoxy.
4. The composition of Claim 3, wherein said alkoxy is selected from the group consisting of methoxy, ethoxy, propoxy, n-butoxy, t-butoxy, and isobutoxy.
5. The composition of Claim 1, wherein R_3 is an alkoxy.
6. The composition of Claim 5, wherein said alkoxy is selected from the group consisting of methoxy, ethoxy, propoxy, n-butoxy, t-butoxy, and isobutoxy.
7. The composition of Claim 1, wherein R_3 is a halogen.
8. The composition of Claim 7, wherein said halogen is chlorine
9. The composition of Claim 7, wherein said halogen is bromine.
10. The composition of Claim 1, wherein R_3 is a perhaloalkyl.
11. The composition of Claim 10, wherein said perhaloalkyl is selected from the group consisting of trifluoromethyl, pentafluoroethyl, and heptafluoropropyl.
12. The composition of Claim 1, wherein R_3 is a heterocyclyl.
13. The composition of Claim 12, wherein said heterocyclyl is selected from the group consisting of furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, triazole, thiadiazole, pyran, pyridine, piperidine, morpholine, thiomorpholine, pyridazine,

pyrimidine, pyrazine, piperazine, triazine, , , and , wherein R is selected from hydrogen and lower alkyl.


14. The composition of Claim 13, wherein said heterocyclyl is pyrrolidine.
15. The composition of Claim 13, wherein said heterocyclyl is morpholine.

16. The composition of Claim 1, wherein R_3 is $-\text{NH}(\text{CO})\text{R}$, wherein R is selected from hydrogen, and lower alkyl.
17. The composition of Claim 16, wherein said alkyl is selected from the group consisting of methyl, ethyl, propyl, n-butyl, t-butyl, and isobutyl.
18. The composition of Claim 1, wherein R_2 and R_3 , taken together along with the two ring carbons to which they are attached form a six-membered heterocyclic ring.
19. The composition of Claim 18, wherein R_2 and R_3 , taken together along with the two




ring carbons to which they are attached form

20. The composition of Claim 1, wherein R_3 or R_4 is an optionally substituted N-sulfonamido or an optionally substituted S-sulfonamido.
21. The composition of Claim 20 wherein R_3 or R_4 has the structure




wherein R_{18} is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl.



22. The composition of Claim 21 wherein R_{18} is phenyl, singly or multiply substituted with C_{1-5} alkyl, C_{1-5} perhaloalkyl, C_{1-5} alkoxy, C_{1-5} perhaloalkyl alkoxy, and N-alkylamido.
23. The composition of Claim 1, wherein R_6 and R_7 are hydrogen.
24. The composition of Claim 1, wherein R_8 is cyano.



25. The composition of Claim 1, wherein R_8 is
26. The composition of Claim 25, wherein X is nitrogen, Y is oxygen and Z_1 and Z_2 are null.
27. The composition of Claim 25, wherein X is nitrogen, Y is NH , Z_1 is oxygen and Z_2 is null.
28. The composition of Claim 25, wherein X is nitrogen, Y is NH , and Z_1 and Z_2 are oxygen.
29. The composition of Claim 24, wherein X is nitrogen, Y is sulfur, Z_1 is $(\text{H})(\text{OH})$ and Z_2 is null.



30. The composition of Claim 1, wherein R_8 is
31. The composition of Claim 30, wherein R_{13} and R_{14} are hydrogen.
32. The composition of Claim 30, wherein R_{13} is lower alkyl and R_{14} are hydrogen.
33. The composition of Claim 32, wherein said alkyl is selected from the group consisting of methyl, ethyl, propyl, n-butyl, t-butyl, and isobutyl.
34. The composition of Claim 1, wherein T is sulfur.
35. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient and a compound having a structure of Formula II or III,



or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof,
wherein

- a) T is selected from the group consisting of oxygen, sulfur, and $-NR_{17}$, wherein R_{17} is selected from the group consisting of hydrogen, lower alkyl, and aryl;
- b) R_{15} and R_{16} are each independently selected from the group consisting of
 - i) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl, aryl, and heteroaryl; and

$n1$ is 0, 1, 2, or 3; and
 - ii) a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of
 - A) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
 - B) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl; and

n_1 is 0, 1, 2 or 3

C) halogen or perhaloalkyl;

D) cyano;

E) nitro;

F) an amino of formula $-(X_3)_{n_3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0 or 1;

G) a thioether or thiol of formula $-(X_6)_{n_6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, aryl, perhaloalkyl, and heteroaryl; and

n_6 is 0, 1, 2 or 3; and

H) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, and heteroaryl;

n_7 and n_9 are each independently 0 or 1;

I) an N-sulfonamido of structure



wherein

R_{18} is lower alkyl, lower heteroalkyl, or a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

(1) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;

(2) an alkoxy of formula $-(X_1)_{n_1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl;

and

n_1 is 0, 1, 2 or 3;

(3) halogen or perhaloalkyl;

(4) cyano;

(5) nitro;

(6) an amino of formula $-(X_3)_{n_3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and

heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0 or 1;

- (7) a thioether or thiol of formula $-(X_6)_{n_6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, perfluoroalkyl, aryl, and heteroaryl; and

n_6 is 0, 1, 2, or 3; and

- (8) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$ wherein


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, and heteroaryl;


n_7 and n_9 are each independently is 0 or 1;

R_{20} is H, C_{1-5} alkyl, C_{1-5} aralkyl, or taken together with R_{18} forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, having the following structure



i is 0, 1, 2, 3, 4;

- J) an S-sulfonamido of formula



wherein R_{18} is a lower alkyl, lower heteroalkyl, or a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

- (1) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- (2) an alkoxy of formula $-(X_1)_{n1}-O-X_2$, where

X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_2 is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl;

and

$n1$ is 0, 1, 2, or 3
- (3) halogen or perhaloalkyl;
- (4) cyano;
- (5) nitro;
- (6) an amino of formula $-(X_3)_{n3}-NX_4X_5$, where

X_3 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_4 and X_5 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_4 and X_5 , taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_3 is 0 or 1;

- (7) a thioether or thiol of formula $-(X_6)_{n_6}-S-X_7$, where

X_6 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl; and

n_6 is 0, 1, 2, or 3; and

- (8) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, and heteroaryl;

n_7 and n_9 are each independently is 0 or 1;

R_{19} is H, C_{1-5} alkyl, C_{1-5} aralkyl, or R_{19} taken together with a portion of the ring to which the S of the S-sulfonamido attaches forms an optionally substituted five-, six-, seven-, or eight-membered heterocyclic ring, having the following structure:



W is independently selected from the group consisting of

- A) hydrogen;
- B) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- C) optionally substituted aryl;
- D) optionally substituted heterocyclyl;
- E) an alkoxy of formula $-(X_{13})_{n13}-O-X_{14}$, where
 X_{13} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_{14} is selected from the group consisting of hydrogen, lower alkyl, aryl, lower perhaloalkyl, and heteroaryl; and

i is 0, 1, 2, 3, 4;

iii) an acyl of formula $-(X_1)_{n1}-C(O)-X_2$, where

- X_1 is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
- X_2 is selected from the group consisting of hydrogen, lower alkyl, aryl, heteroaryl, hydroxy, alkoxy, amino, and $-NH-X_3$,
 where X_3 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, amino, and amide; and
 $n1$ is 0, 1, 2 or 3; and

iv) cyano;

v) nitro;

vi) an amino of formula $-(X_{15})_{n15}-NX_{16}X_{17}$, where

- X_{15} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;
- X_{16} and X_{17} are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X_{16} and X_{17} , taken together with the nitrogen to which they are

attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n_{15} is 0 or 1; and

vii) a thioether or thiol of formula $-(X_{22})_{n_{22}}-S-X_{23}$, where

X_{22} is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_{23} is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl; and


n_{22} is 0, 1, 2, or 3; and

c) R_8 is selected from the group consisting of

i) hydrogen;

ii) optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;

iii) cyano;




wherein

X is selected from CH and nitrogen;

Y is selected from the group consisting of CH_2 , NH, oxygen and sulfur;

Z_1 and Z_2 are each independently selected from the group consisting of null, oxygen, sulfur, and $CR_{11}R_{12}$,

wherein R_{11} and R_{12} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy; and



wherein R_{13} and R_{14} are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH_2 , halogen, perhaloalkyl, and hydroxy;

- vi) optionally substituted acyl of the formula $-C(O)R_E$, wherein $HOC(O)R_E$ is any pharmaceutically acceptable acid;
- d) R_6 and R_7 are each independently selected from the group consisting of hydrogen and lower alkyl.

36. The composition of Claim 35, wherein R_{15} is an optionally substituted five-, six-, seven-, or eight-membered carbocyclic or an optionally substituted heterocyclic aliphatic ring, or an optionally substituted five-membered or six-membered heteroaryl ring or an optionally substituted six-membered aryl ring.

37. The composition of Claim 35, wherein T is sulfur.

38. The composition of Claim 36, wherein T is sulfur.


39. The composition of Claim 36, wherein R_{15} is an optionally substituted phenyl.

40. The composition of Claim 39, wherein the phenyl is further substituted with optionally substituted N-sulfonamido or optionally substituted S-sulfonamido.

41. The composition of claim 40 wherein said N-sulfonamido or S-sulfonamido is further substituted with an optionally substituted aryl.

42. The composition of claim 41 wherein said aryl is singly or multiply substituted with C_{1-5} alkyl, C_{1-5} perhaloalkyl, C_{1-5} alkoxy, C_{1-5} perhaloalkyl alkoxy, and N-alkylamido.


43. A compound of Formula IV,



or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof,

wherein

a) [A] is



wherein o and p are each independently 0, 1, 2, or 3;

R' and R'' are each independently selected from the group consisting of hydrogen and lower alkyl;

R₁₈ is a lower alkyl, a lower heteroalkyl, or a five-, six-, seven-, or eight-membered carbocyclic or heterocyclic aliphatic ring, or a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, each optionally substituted with one or more substituents selected from the group consisting of

i) optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl;

ii) an alkoxy of formula -(X₁)_{n1}-O-X₂, where

X₁ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X₂ is selected from the group consisting of hydrogen, lower alkyl, lower perhaloalkyl, aryl, and heteroaryl; and

n₁ is 0, 1, 2 or 3;

iii) halogen, partially halogenated alkyl, or perhaloalkyl;

iv) cyano;

v) nitro;

vi) an amino of formula -(X₃)_{n3}-NX₄X₅, where

X₃ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X₄ and X₅ are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, and heteroaryl; or X₄ and X₅, taken together with the nitrogen to which they are attached, form a five-membered or six-membered heteroaromatic or heteroaliphatic ring; and

n₃ is 0 or 1;

vii) a thioether or thiol of formula -(X₆)_{n6}-S-X₇, where

X₆ is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_7 is selected from the group consisting of hydrogen, lower alkyl, perfluoroalkyl, aryl, and heteroaryl; and n_6 is 0, 1, 2, or 3; and

viii) an amide of formula $-(X_7)_{n_7}-NH-C(O)-X_8$ or $-(X_9)_{n_9}-C(O)-NH-X_{10}$


X_7 and X_9 are each independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, aryl, and heteroaryl;

X_8 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, and amide; and

X_{10} is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower heteroalkyl, aryl, and heteroaryl;

n_7 and n_9 are each independently is 0 or 1;

R_{19} is H, C_{1-5} alkyl, or R_{19} taken together with R_1 forms a five-, six-, seven-, or eight-membered heterocyclic ring, and o is 0, and the compound of formula IV has the following structure:




W is independently selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C_1-C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) optionally substituted aryl;
- iv) optionally substituted heterocyclyl;

- v) an alkoxy of formula $-(X_{13})_{n_{13}}-O-X_{14}$, where
 X_{13} is selected from the group consisting of lower alkylene,
 lower alkenylene, lower alkynylene, aryl, and heteroaryl;
 X_{14} is selected from the group consisting of hydrogen, lower
 alkyl, lower perhaloalkyl, aryl, and heteroaryl; $n_{13} = 0, 1, 2$, or
 3; and

wherein i is 0, 1, 2, 3;


R_{20} is H, C_{1-5} alkyl, or R_{20} taken together with R_{18} forms a five-, six-, seven-, or eight-membered heterocyclic ring, having the following structure:



- b) wherein each R_1 is each independently selected from the group consisting of


- i) hydrogen;
- ii) lower alkyl;
- iii) lower alkylene;
- iv) halogen, partially halogenated alkyl, or perhaloalkyl;
- v) an alkoxy or perhaloalkoxy;

- c) wherein [C] is



- d) wherein R_8 is selected from the group consisting of

- i) hydrogen;
- ii) optionally substituted C_1-C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;
- iii) cyano;




wherein

X is selected from CH and nitrogen;

Y is selected from the group consisting of CH₂, NH, oxygen and sulfur;

Z₁ and Z₂ are each independently selected from the group consisting of null, oxygen, sulfur, and CR₁₁R₁₂,

wherein R₁₁ and R₁₂ are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH₂, halogen, perhaloalkyl, and hydroxy; and



wherein R₁₃ and R₁₄ are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, aryloxy, NH₂, halogen, perhaloalkyl, and hydroxy;

vi) optionally substituted acyl of the formula -C(O)R_E, wherein HOC(O)R_E is any pharmaceutically acceptable acid;

vii) or R₈ is equivalent to the balance of Formula IV to form a disulfide dimer; and

e) wherein R₆ and R₇ are each independently selected from the group consisting of hydrogen and lower alkyl.







44. The compound of claim 43 wherein R₁₉ and R₂₀ are each independently H or C₁₋₅ alkyl, and o and p are 0.















45. The compound of Claim 43, wherein R₁₈ is optionally substituted phenyl.













46. The compound of Claim 43 wherein said R₈ is optionally substituted acyl which forms the pharmaceutically acceptable acid HOC(O)R_E upon thioester hydrolysis.

47. The compound of Claim 46 wherein said pharmaceutically acceptable acid HOC(O)R_E is selected from the group consisting of N,N-diethylglycine; 4-ethylpiperazinoacetic acid; ethyl 2-methoxy-2-phenylacetic acid; N,N-dimethylglycine; (nitrophenoxysulfonyl)benzoic acid, acetic acid, maleic acid, fumaric acid, benzoic acid, tartronic acid, glutamic acid, aspartic acid, proline, D-amino acids, butyric acid, palmitic acid, stearic acid, oleic acid, pipecolic acid, phosphonic acid, phosphoric acid, pivalate (trimethylacetic acid), succinic acid, cinnamic acid, anthranilic acid, salicylic acid, lactic acid, and, pyruvic acids.



48. The compound of claim 43 wherein R_8 is H and the compound is selected from the group of compounds consisting of








































49. The compound of claim 43 wherein R_8 is an optionally substituted acyl and the compound has a structure selected from the group consisting of























50. The compound of claim 43 wherein R_8 is equivalent to the balance of structure IV so as to form a disulfide dimer and the compound has a structure selected from the group consisting of














51. A compound having structure of Formula V or VI, VII, or VIII:



or a pharmaceutically acceptable salt amide, ester or prodrug thereof
wherein

- R_6 and R_7 are each independently selected from the group consisting of hydrogen and lower alkyl;
- R_8 is selected from the group consisting of H, acyl, and heterocyclyl, or R_8 is equivalent to the balance of the compound so as to form a disulfide;
- R_{22} is selected from the group consisting of C_{1-5} alkyl, C_{1-5} perhaloalkyl, C_{1-5} alkoxy, C_{1-5} perhaloalkyl alkoxy, C_{1-5} perhaloalkoxy, and N-alkylamido;
- $n = 0, 1, 2, 3$.

52. A compound having structural formula V according to claim 51 wherein said compound has the structural formula:



and wherein R_{22} is lower perfluoroalkoxy and R_8 is a thiol protecting group or R_8 is equivalent to the balance of the compound so as to form a disulfide.

53. The compound according to Claim 52 wherein R_{22} is $-\text{OCF}_3$.
54. The compound according to Claim 52 wherein R_8 is acetyl.
55. The compound of Claim 43 wherein said compound of Formula IV or pharmaceutically acceptable salt, amide, ester or prodrug thereof is capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
56. A pharmaceutical composition comprising the compound of claim 43 Formula IV or pharmaceutically acceptable salt, amide, ester or prodrug thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
57. A pharmaceutical composition comprising a compound of claim 51 Formula IV or pharmaceutically acceptable salt, amide, ester or prodrug thereof and a pharmaceutically acceptable carrier, diluent, or excipient.
58. The compound of claim 51 wherein said compound of Formula V, VI, VII, or VIII or pharmaceutically acceptable salt, amide, ester or prodrug thereof is capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
59. The pharmaceutical composition of claim 1 wherein said compound of Formula I, or pharmaceutically acceptable salt, amide, ester or prodrug thereof is capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
60. The pharmaceutical composition of claim 35 wherein said compound of Formula II and III or pharmaceutically acceptable salt, amide, ester or prodrug thereof is capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
61. A method of modulating the catalytic activity of HDAC comprising contacting said HDAC with a pharmaceutical composition of any one of Claims 1, 35, 56, and 57.
62. A method of identifying a carbonyl compound that modulates the function of HDAC, comprising the following steps:
- a) contacting cells expressing HDAC with a compound or composition of any one of Claims 1, 35, 43 or 51; and
 - b) monitoring an effect of said compound or composition upon said cells.
63. The method of Claim 62, wherein said effect is selected from the group consisting of a change in cell phenotype, a change in cell proliferation, a change in the catalytic activity of HDAC, and a change in the interaction between HDAC and a binding partner.
64. A method of treating disease in an individual, comprising identifying an individual in need thereof and administering an effective amount of a pharmaceutical composition of any one of Claims 1, 35, 56 or 57 to said individual.

65. The method of Claim 64, wherein said disease is a hyper-proliferative condition of the human or animal body.
66. The method of Claim 65 wherein the hyper-proliferative condition is selected from the group consisting of colon cancer, breast cancer, ovarian cancer, lung cancer and prostate cancer.
67. The method of Claim 65 wherein the hyper-proliferative condition is selected from the group consisting of cancer of the pancreas, cervix uteri, kidney, brain and central nervous system.
68. The method of Claim 65 wherein the hyper-proliferative condition is selected from the group consisting of non-Hodgkin's lymphomas, multiple myeloma and hematopoietic malignancies, leukemias, Chronic Lymphocytic Leukemia, and lymphomas.
69. The method of Claim 64, wherein said disease is selected from the group consisting of a neurological disorder, and polyglutamine-repeat disorders.
70. The method of Claim 69, where the polyglutamine-repeat disorder is selected from the group consisting of Huntington's disease, Spinocerebellar ataxia 1 (SCA 1), Machado-Joseph disease (MJD)/Spinocerebellar ataxia 3 (SCA 3), Kennedy disease/Spinal and bulbar muscular atrophy (SBMA) and Dentatorubral pallidolusyan atrophy (DRPLA).
71. The method of Claim 64, wherein said disease is an anemia or thalassemia.
72. The method of Claim 71, wherein the thalassemia is Sick Cell Disease.
73. The method of Claim 64, wherein said disease is an inflammatory condition.
74. The method of Claim 73, wherein the inflammatory condition is selected from the group consisting of Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), ulcerative colitis and psoriasis.
75. The method of Claim 64, wherein said disease is an autoimmune disease.
76. The method of Claim 75, wherein the autoimmune disease is selected from the group consisting of Systemic Lupus Erythromatosus (SLE) and Multiple Sclerosis (MS).
77. The method of Claim 64, wherein said disease is a cardiovascular condition.
78. The method of Claim 77, wherein the cardiovascular condition is selected from the group consisting of cardiac hypertrophy and heart failure.
79. Use of a compound or composition according to any one of claims 1, 35, 43 or 51 for the manufacture of a medicament for use in the treatment of a condition mediated by HDAC.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110418 A3

(51) International Patent Classification⁷: **C07C 331/04**,
C07D 319/18, C07C 331/12, 331/10, C07D 277/16,
277/36, C07C 323/22, 323/29, C07D 277/52, C07C
323/67, A61K 31/26, 31/357, 31/426, 31/12, 31/167

(21) International Application Number:
PCT/US2004/018502

(22) International Filing Date: 10 June 2004 (10.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/477,721 10 June 2003 (10.06.2003) US

(71) Applicant (for all designated States except US): **KALYP-
SYS, INC.** [US/US]; 11099 North Torrey Pines Road, La
Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WASH, Paul, L.**
[US/US]; 3620 Park Blvd., Apt. 11, San Diego, CA
92103 (US). **WILEY, Brandon, M.** [US/US]; 241 La Veta
Avenue, Encinitas, CA 92024 (US). **HASSIG, Christian**
[US/US]; 8818 Capceno Road, San Diego, CA 92126
(US). **MALECHA, James, W.** [US/US]; 4482 Philbrook
Square, San Diego, CA 92130 (US). **NOBLE, Stewart,
A.** [GB/US]; 5632 Shannon Ridge Lane, San Diego, CA
92130 (US).

(74) Agent: **BLAYLOCK, Richard, L.**; Pillsbury Winthrop,
LLP, 11682 El Camino Real, Suite 200, San Diego, CA
92130-1593 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only


Published:

— with international search report


(88) Date of publication of the international search report:
17 March 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.


(54) Title: CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DIS-
EASE



(I)



(II)



(III)

(57) Abstract: Disclosed herein are carbonyl compounds of Formula (I), (II) or (III), and others as described herein. Also dis-
closed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anemias,
thalassemias, inflammatory conditions, autoimmune diseases and cardiovascular conditions, using the compounds of the invention.
In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2004/018502

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C331/04 C07D319/18 C07C331/12 C07C331/10 C07D277/16
C07D277/36 C07C323/22 C07C323/29 C07D277/52 C07C323/67
A61K31/26 A61K31/357 A61K31/426 A61K31/12 A61K31/167

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/70675 A (METHYLGENE INC) 27 September 2001 (2001-09-27) claims; examples 97-102,131-134,159; table 2	1,2,23, 34,59, 61-79
X	WO 02/069947 A (METHYLGENE INC) 12 September 2002 (2002-09-12) claims 12-91	1,2,23, 34,59, 61-79
X	WO 02/20500 A (ICOS CORP) 14 March 2002 (2002-03-14) claims 10-26; examples 96,97 page 47, line 11 - page 49, line 7 -/--	1,13,15, 23,34, 59,64-68

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search

14 December 2004

Date of mailing of the international search report

28/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seufert, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/018502

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 24 36 263 A (HOECHST AG) 12 February 1976 (1976-02-12) example 117a -----	43,44, 46,47
X	DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002310127 retrieved from STN Order Number: Stock3S-03848 & "Interbioscreen Compound Library" 9 May 2003 (2003-05-09), INTERBIOSCREEN LTD. , MOSCOW 121019, RUSSIA -----	43-45
X	DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002310128 retrieved from STN Order Number: BAS 1259338 abstract & "AsInEx Express Gold Collection" 23 April 2003 (2003-04-23), ASINEX , MOSCOW 123182, RUSSIA -----	43-45
X	WO 01/90100 A (BEST DESMOND JOHN ; BRUTON GORDON (GB); WALKER GRAHAM (GB); RANA KISHO) 29 November 2001 (2001-11-29) example 13, step 3 -----	43,44
X	EP 0 055 458 A (HOECHST AG) 7 July 1982 (1982-07-07) page 21, line 13 - line 14 page 24, line 17 - line 18 -----	43,44
X	DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002310129 Database accession no. BRN 5532185 abstract & BANKS, R. BRUCE ET AL.: J. MED. CHEM., vol. 26, no. 12, 1983, pages 1780-84, -----	1,23,59, 64
X	DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002310130 Database accession no. BRN 7994375 abstract & BAN, MASAKAZU ET AL.: BIOORG. MED. CHEM., vol. 6, no. 7, 1998, pages 1069-76, ----- -/--	1,3,4, 23,59,64

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/018502

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002310131 Database accession no. BRN 506166 abstract & GREEN, A. P.; MANGAN F. R.: J. PHARM. PHARMACOL., 1980, pages 319-22, -----</p>	35,37, 60,64,73
X	<p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002310132 Database accession no. BRN 7929777 abstract & JANUSZ, JOHN M. ET AL.: J. MED. CHEM., vol. 41, no. 7, 1998, pages 1112-23, -----</p>	1,23,34, 59,64,74
X	<p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002310133 Database accession no. BRN 7777930 abstract & ABDEL, A. H. ET AL.: BOLL. CHIM. FARM., vol. 136, no. 3, 1997, pages 262-265, -----</p>	1,23,59, 64

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/018502

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 61-78 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/018502

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0170675	A	27-09-2001	AU 4870101 A	03-10-2001
			CA 2404002 A1	27-09-2001
			EP 1280764 A2	05-02-2003
			WO 0170675 A2	27-09-2001
			JP 2003528074 T	24-09-2003
			US 2002115826 A1	22-08-2002
WO 02069947	A	12-09-2002	CA 2434601 A1	12-09-2002
			DE 10295684 T0	20-11-2003
			GB 2389365 A	10-12-2003
			WO 02069947 A2	12-09-2002
			JP 2004520421 T	08-07-2004
			US 2003152557 A1	14-08-2003
			US 2003148970 A1	07-08-2003
			US 2002137162 A1	26-09-2002
WO 0220500	A	14-03-2002	AU 8843201 A	22-03-2002
			EP 1351946 A2	15-10-2003
			WO 0220500 A2	14-03-2002
			US 2002165218 A1	07-11-2002
DE 2436263	A	12-02-1976	DE 2436263 A1	12-02-1976
			AT 344160 B	10-07-1978
			AT 577075 A	15-11-1977
			AT 360520 B	12-01-1981
			AT 781477 A	15-06-1980
			AT 360985 B	10-02-1981
			AT 781577 A	15-07-1980
			AT 360521 B	12-01-1981
			AT 781677 A	15-06-1980
			AT 360522 B	12-01-1981
			AT 781777 A	15-06-1980
			AU 501320 B2	14-06-1979
			AU 8339175 A	27-01-1977
			BE 831794 A1	28-01-1976
			CA 1054596 A1	15-05-1979
			CH 617431 A5	30-05-1980
			CH 624677 A5	14-08-1981
			CH 624678 A5	14-08-1981
			CH 623316 A5	29-05-1981
			CY 1008 A	02-08-1979
			DD 121112 A5	12-07-1976
			DK 340475 A ,B,	28-01-1976
			ES 439593 A1	16-06-1977
			ES 455015 A1	16-12-1977
			ES 455018 A1	16-12-1977
			ES 455019 A1	16-12-1977
			ES 455020 A1	16-12-1977
			FI 752131 A ,B,	28-01-1976
			FR 2282882 A1	26-03-1976
			GB 1513948 A	14-06-1978
			HK 40579 A	29-06-1979
			HU 172659 B	28-11-1978
			IE 42441 B1	13-08-1980
			IL 47779 A	31-01-1979
			JP 1285205 C	09-10-1985
			JP 51054555 A	13-05-1976
			JP 60006945 B	21-02-1985

INTERNATIONAL SEARCH REPORT

¹ Information on patent family members

International Application No
PCT/US2004/018502

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 2436263	A	LU 73069 A1	24-03-1977
		MX 3514 E	14-01-1981
		NL 7508848 A ,B,	29-01-1976
		NO 752636 A ,B,	28-01-1976
		SE 431207 B	23-01-1984
		SE 7508476 A	28-01-1976
		US 4061761 A	06-12-1977
		US 4125614 A	14-11-1978
		ZA 7504772 A	30-06-1976
WO 0190100	A	29-11-2001	
		AU 6746801 A	03-12-2001
		BR 0111074 A	24-06-2003
		CA 2410294 A1	29-11-2001
		CN 1440400 T	03-09-2003
		CZ 20023853 A3	14-05-2003
		WO 0190100 A1	29-11-2001
		EP 1289980 A1	12-03-2003
		HU 0302121 A2	28-10-2003
		JP 2004501108 T	15-01-2004
		NO 20025549 A	24-01-2003
		NZ 522594 A	28-05-2004
		PL 360116 A1	06-09-2004
		US 2004024066 A1	05-02-2004
		ZA 200209514 A	15-10-2003
EP 0055458	A	07-07-1982	
		DE 3049460 A1	29-07-1982
		AR 231134 A1	28-09-1984
		AR 231978 A1	30-04-1985
		AT 11778 T	15-02-1985
		AU 542670 B2	28-02-1985
		AU 7906881 A	08-07-1982
		CA 1173836 A1	04-09-1984
		DE 3168978 D1	28-03-1985
		DK 581181 A	01-07-1982
		EP 0055458 A2	07-07-1982
		ES 8305342 A1	01-07-1983
		ES 8402829 A1	16-05-1984
		ES 8308549 A1	01-12-1983
		ES 8308550 A1	01-12-1983
		ES 8308551 A1	01-12-1983
		FI 814175 A	01-07-1982
		HU 184976 B	28-11-1984
		IE 52259 B1	19-08-1987
		IL 64653 A	29-09-1985
		JP 57134472 A	19-08-1982
		NO 814468 A ,B	01-07-1982
		US 4421757 A	20-12-1983
		ZA 8108968 A	24-11-1982